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Abstract 
TITLE OF THE ABSTRACT:  
Assessment of attitudes towards participation, willingness to participate, and competence 
to participate in Randomized Controlled Trials:  a cross-sectional qualitative and 
quantitative survey of psychiatric patients and key family members using the 
“Prospective Preference Assessment” method and the MacArthur Competence 
Assessment Tool for Clinical Research (MaCAT-CR). 
DEPARTMENT: Department of Psychiatry 
NAME OF THE CANDIDATE: Donae Elizabeth George 
DEGREE AND SUBJECT: MD Psychiatry 
NAME OF THE GUIDE: Professor Prathap Tharyan 
OBJECTIVES: To understand the perspectives of Indian patients undergoing treatment 
for major psychiatric disorders, and of their relatives, regarding participation in 
randomised clinical trials,and to assess their competence to consent. 
METHODS:A cross-sectional quantitative and qualitative study using the “Prospective 
Preference Assessment” method on moderately-ill, consenting, psychiatric inpatients, and 
their relatives, assessed their attitudes to participation in randomised clinical trials 
(RCTs); their comprehension about information regarding two hypothetical trials; their 
willingness to participate; and the barriers and facilitators to participation. Clinical 
assessments of the capacity to consent were supplemented, in a sub-set, by independent 
assessments using the MacArthur Competence Assessment Tool for Clinical Research 
(MaCAT-CR). Quantitative data were presented as frequencies and qualitative data from 
audio-recorded, verbatim transcripts, were analysed for themes using the “Grounded 
Theory” framework.   
RESULTS: All twenty participants (9 patients, 11 relatives) endorsed the need for RCTs 
and their methods; and altruism as a motive for participation. Only 50% were willing to 
participate in the hypothetical trials. Comprehension of information sheets was sub-
optimal. Trust in doctors and organisations, and the opinions of family members’ 
facilitated participation. Unfavourable risk/benefit ratios, the use of placebos, distrust in 
doctors and organisations, financial and other hardships, and opinions of family members 
were barriers. The majority of participants judged competent on clinical assessment failed 





Randomized control trials (RCTs) are considered to provide the least biased method 
of evaluating the efficacy of drugs and other interventionsused in healthcare [1]. Well 
conducted RCTs form an integral part of the external research evidence that is meant 
to be summarised in systematic reviews and incorporated with clinical expertise, and 
the values and preferences of patients, in the endeavour called “Evidence-Based 
Medicine” [2]. For RCTs to produce valid and reliable results, their methods need to 
be robust in order to ensure that biases have been minimised, and that known and 
unknown confounders are balanced across treatment arms at the start of the trial [3, 
4].  However, these methods used in RCTs that increase the reliability of their results 
differ from the components of clinical care that patients and their relatives expect 
from clinicians. This may give rise to ethical issues when vulnerable populations are 
enrolled in such trials without fully appreciating the potential risks involved, and the 
deviations in clinical trials from usual clinical practice.  
Over the past decade, there has been an increase in the number of trials “out-sourced” 
to low and middle income countries, in order to ensure that adequate numbers of 
people are recruited, so that the required sample sizes are adequate for the purposes of 
scientifically valid analyses [5]. This shift in the settings where clinical trials are 
being conducted have been met with concern from some quarters about the need for 
such trials, and the potential for coercion and misinformation that may be used to 
recruit illiterate participants from low socio-economic backgrounds. They have also 
been welcomed by others due to the potential for financial benefits, and the 
improvements in knowledge and infra-structure that participation in such trial is 
associated with [6, 7].  
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In order to protect participants recruited to such trials, current International and Indian 
ethical guidance emphasises the importance of informed consent to ensure that 
patients and their care-givers participate in these trials after having understood the 
potential benefits, risks and procedures that participation entails; however, this 
consent needs to be voluntary, fully informed, and freely given [8-10]. Concerns have 
been raised about the quality of informed consent obtained in developing countries, 
and also of the validity of consent provided by psychiatric patients; and although 
evidence obtained from Indian patients regarding their views to participation is 
gradually emerging, this is insufficient to adequately inform the design and conduct of 
trials in Indian populations that meetethical standards, and yet also meet the 
requirements of scientific validity [5-7]. 
This pilot study was conducted in order to ascertain the views of psychiatric in-
patients undergoing treatment at ageneral hospital psychiatric department, and of their 
key relatives, regarding their willingness to participate in clinical trials in general, and 
their willingness to participate in a hypothetical trial in particular. The barriers and 
facilitators to participation were also explored. Their comprehension of the 
information provided as part of the informed consent process, and their capacity to 
consent to participate were additionally investigated.  
This study used a method called “Prospective Preference Assessment”that is aimed at 
improving recruitment for future trials, by simulating recruitment, thereby helping 
forecast enrolment rates, identifying problem areas, and illuminating differences 
between participants and non-participants [11, 12]. A cross-sectional framework and a 
mixture of quantitative and qualitative methodswere used in this study to explore the 
attitudes of psychiatrically ill patients and their relatives towards participation in 
clinical trials, and of this method of ascertainment of this information. Knowledge of 
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these attitudes and opinions will help in developing patient information materials 
catering to relevant and specific needs of Indian patients. Understanding the 
facilitators and barriers to participation in trials in this population will help in 
designing trials that are more patient-friendly and effective. Evaluating their 
comprehension of the information provided and assessing their capacity to provide 
valid informed consent will help in understanding the ways in which information 
should ideally be presented in order to be better understood; and will also inform 
those designing and conducting trials about the methods to be used to ensure that the 
consent given is valid, while ensuring that the methods important to ensure reliable 
results are also optimally utilised. Such insights into the mind-set of this vulnerable 
population can guide clinicians to plan better clinical trials in psychiatry that are both 




Objectives and Aims 
The objectives of this cross-sectional, quantitative and qualitative study were to 
understand the perspectives of a sample of Indian patients undergoing treatment for 
major psychiatric disorders, and of their relatives, regarding participation in 
randomised clinical trials, in order to inform the design and conduct of future 
randomised clinical trials involving Indian participants, particularly those with 
psychiatric disorders.  
The specific aims of this study were: 
1. To explore the attitudes of psychiatrically ill patients and their relatives 
towards participation in RCTs in general; and about the specific components of the 
methods of RCTs that minimize the risk of bias and increase the reliability of their 
outcomes, in particular; by presenting them with information about a hypothetical 
RCT that they are invited to participate in.   
2. To assess the comprehension of psychiatrically ill patients and their relatives 
regarding the information provided in informed consent forms that was provided to 
them during the process of informed consent towards participation in the hypothetical 
RCT, in order to understand the proportions of patients with psychiatric disorders, and 
their relatives, who are able to fully comprehend the information provided so that 
validity of the consent obtained could be assessed. 
3. To assess the willingness of psychiatrically ill patients, and of their relatives to 
participate in the hypothetical RCT, and to understand their reasons for participation 
or non-participation; in order to identify the proportions who would be willing to 
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participate in future RCTs, and to understand the cultural and other barriers and 
facilitators to participation. 
3. To assess the competence of the psychiatrically ill participants in this 
study,and their relatives, to provide valid consent to participate in research,based 
onclinical judgements obtained from standard psychiatric interviews; and to compare, 
in a subset of participants in this study, the correlation between the judgements of a 
trainee-psychiatrist and the independent assessment of competence obtained by an 
experienced consultant psychiatrist using the MacArthur Competence Assessment 




Review of Literature 
This section selectively reviews the existing international and Indian literature 
regarding the role of RCTs and other study designs in providing reliable evidence to 
inform healthcare decisions; the methods used in RCTs to ensure reliable results; and 
the ethical issues that arise due to the use of these methods, including the issue of 
“therapeutic misconception” that arises when patients seeking clinical care are 
involved in research. This section also briefly reviews the specific problems involved 
in including vulnerable populations in research, the empirical evidence from India and 
elsewhere regarding the attitudes of participants in clinical trials and their 
comprehension and capacity to consent to research. The methods used in such studies 
are also reviewed, as well as the instruments used in such research, in order to provide 
information relevant to the methods used in this study, and to clarify the results and 
interpretations from this study.  
Generating reliable evidence for the effects of interventions: the importance of 
randomized controlled trials 
Every question for which an answer is sought from research should ideally utilise a 
research design that is best suited to answer that particular question [3, 4]. 
Randomized Controlled Trials (RCTs) are considered the least-biased experimental 
design to evaluate the efficacy (and short-term safety) of interventions used in health 
care [1-4]. In the hierarchy of study designs that range from the designs most prone to 
bias to those least likely to introduce bias, RCTs (and systematic reviews of RCTs) 
are considered as the “Gold Standard” for evaluating the effects of interventions used 
in medicine and in healthcare [13]. Evidence for the efficacy of interventions derived 
from case series cannot provide reliable evidence since, in the absence of a control 
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group that did not receive the experimental intervention, one cannot be entirely sure 
that the differences in changes in clinical outcomes from baseline are due to the 
effects of the intervention alone [1-4]. Having a control group (consisting of no 
intervention, or a placebo intervention, or standard care, or another active 
intervention) helps to determine if any differences in outcomes between the 
experimental and control groups could be accounted for by chance (random 
variations), or as a result of spontaneous remission of the condition being treated, that 
is very likely in some conditions, such as psychiatric disorders [1-4, 14, 15].However, 
for the interpretation of the results of RCTS to be accurate, the participants in the 
experimental and control arms should be identical in all respects at the beginning of 
the trial in terms of confounders (demographic or illness variables that could 
independently result in better or worse outcomes other than that due to the 
experimental or control intervention) [3, 4, 14, 15].In an RCT, the process of 
randomisation creates groups that have similar prognoses at the outset; this is 
achieved by randomisation resulting in known and unknown confounders being 
balanced between the intervention arms, provided the sample size is reasonably large 
[3]. 
Observational studies (cohort studies and case-control studies) offer the best study 
design to answer questions regardingthe causation of diseases; and for detecting rare 
events, or of adverse events that may occur much later than the duration of the 
average RCT [1, 3, 16]. Observational study designs also offer an alternative to RCTs 
when RCTs are impractical, or are considered unethical [17]. However, observational 
evidence may beaffected by selection biases due to confounding [1-4, 13-15]. 
Reliance on observational data to inform decisions regarding interventions can be 
seriously misleading, and empirical evidence indicates that observational studies 
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generally tend to over-estimate the beneficial effects of interventions compared to 
RCTs, though the direction of benefit may not always favour the experimental arm; 
and is unpredictable [18, 19]. One example of the misleading effects that reliance on 
observational evidence can produce was the previous wide-spread recommendation of 
using hormone replacement (HRT) for prolonged periods in peri-menopausal and 
post-menopausal women to achieve better cardiovascular outcomes that was based on 
observational data;however, a systematic review of RCTs concluded that long-term 
HRT was associated not only with a higherrisk of developing adverse cardiovascular 
outcomes; there was also evidence for a higher risk of developing breast and colon 
cancer, and even dementia in older,previously healthy, women [20]. Even controlled 
clinical trials that are not randomized are not reliable in their estimates of effects due 
to the possibility of selection bias [19]. 
Key issues in RCTs that minimise the risk of bias and yield valid results 
The various biases that can result in outcome estimates that deviate from the “truth” 
or yield wrong results that were demonstrated in empirical research are: 
a. Selection bias: Selection bias refers to the imbalance in the experimental and 
control groups with regard to important prognostic variables at the start of the trial 
that result in outcome estimates that favour those with a better prognosis, rather 
than being due any of the interventions or control conditions [1-4]. Selection bias 
can be minimised by the process of randomisation, where each eligible participant 
has an equal chance of being allocated to the experimental or the control 
intervention and this can be best achieved if the process of creating the random 
sequence is done using methods used to generate a random sequence that can be 
concealed from those who recruit participants to the trial. In other words, the 
method used to generate the randomisation sequence should ensure that allocation 
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to intervention(s) or the control condition could not be predicted beforehand by 
the trial participant or the person recruiting participants. Therefore methods of 
randomisation such as using alternation, or days of the week, or any other method 
that cannot be concealed does not fulfil this requirement [3]. Methods to create a 
randomisation sequence that do fulfilthis requirement include simple techniques 
such as tossing a coin, drawing lots or referring to a table of random numbers, to 
more technologically-evolved methods such as using computer-based or online 
sources to generate the randomisation sequence. Concealing the randomisation 
sequence from those who recruit participants (called allocation concealment) can 
then be ensured so that the process of randomisation cannot be subverted by 
knowledge of the trial arm that the next participant would be allocated to. This can 
be achieved by using serially numbered, sealed, opaque envelopes containing the 
allocated treatment that is known only to the person generating the random 
sequence and that is opened only at the point of recruitment by a separate person 
who has no access to the randomisation code. Even more fool-proof methods are 
used such as central randomisation and allocation to intervention arms using inter-
active voice response systems at a remote site, or by dispensing medications from 
pre-packed, serially numbered containers with the interventions controlled by the 
pharmacist that ensures that other investigators are unaware of which of the trial 
arms the participants would be allocated to. Randomisation therefore is a two-
stage process wherein generation of the random sequence is followed by, or 
combined with, concealing the intended allocation till recruitment. The process of 
randomization (and concealment of allocation), if properly done will balance 
known and unknown confounders, such as age, sex, severity or duration of disease 
or lifestyle variations, and thereby minimize the likelihood of selection bias. 
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Empirical evidence demonstrates that trials that do not ensure allocation 
concealment of the random sequence are associated with over-estimates of 
treatment efficacy usually favouring the experimental intervention by as much as 
38% [19]. 
b. Performance bias: This refers to bias introduced by knowledge of treatment 
allocation whereby additional treatments are given to one group and not to the 
other, or ways in which the groups are treated in different ways so that the 
outcome estimates are influenced by this differential treatment rather than due to 
the effects of the experimental or control treatments [1-4].  Preventing those 
providing treatments from knowing what treatment is being provided to 
participants can be achieved by “blinding” or “masking’ the interventions by 
using identical tablets or capsules (whether they are placebos or active 
interventions), or the “double dummy” techniques, where each participant gets an 
active intervention and a dummy or placebo intervention, in order to prevent 
investigators and participants from knowing the nature of the allocated 
intervention.  
c. Detection bias: This refers to bias introduced in assessing, or reporting, outcomes 
caused again by knowledge of the allocated intervention and influenced by the 
pre-conceived impressions by the person assessing outcomes, or the trial 
participants, about the efficacy and safety of the interventions. These impressions 
may affect the results of the trial and have also been shown to affect the estimates 
of efficacy and safety of trials in ways not actually due to the interventions being 
evaluated [19]. Blinding the participant and the outcome assessor  to the allocated 
intervention, by ensure adequate allocation concealment and using “masking,’ will 
ensure that detection bias is minimised; though this is more important for 
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subjectively reported outcomes such as depression or pain, rather than for 
objectively ascertained outcomes, such as death or an automated blood result [1-
4].   
d. Attrition bias: If those who drop out from the trial,from among those randomised, 
are not accounted for in the analyses, then false estimates of efficacy and safety 
may occur, especially if the reasons for dropping out are related to lack of efficacy 
of the allocated treatment or due to their adverse events. The importance of 
attrition bias in providing wrong or biased outcome estimates depends on the 
proportions of those dropping out, and particularly if there is a differential drop-
out rate between the experimental and control arms [3]. Methods used in analyses 
that compare the results between those who complete the trial according to the 
trial protocol and those who were analysed according to the arm in which they 
were randomised, irrespective of whether they completed the trial (intention-to-
treat), will help assess if attrition bias contributed to wrong estimates of efficacy 
or safety [1-4].  
e. Reporting biases: This refers to the publication of the results of clinical trials, or 
the selective reporting of certain outcomes and not of other outcomes, or reporting 
the results in ways that were not intended in the trial protocol, that depend on 
whether the results were statically significant, and favoured the experimental 
intervention [1-4,21-24].  
While many other issues in the design, conduct, and reporting of clinical trials can 
impact on the accuracy and the reliability of their effect estimates, the above biases 
have been demonstrated in empirical research as having the greatest impact on 
whether the results of the trial deviate substantially from the actual results (internal 
validity) [1-4,19]. This internal validity of the trial’s results is determined by the 
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trial’s design and methods. External validity refers to the generalizability of the 
results to other settings and populations and this depends on the similarities between 
the setting, populations, methods, and outcomes used in the trial and those where the 
intervention is to be used. Hence, if the exclusion criteria are too stringent, or if the 
comparisons or ways of evaluating outcomes differ from those used in clinical care, 
then the results of the trial may not be applicable to clinical situations that prevail in 
the real world.  
Reporting scientific methods and ethical conduct in clinical trial publications 
In order that RCTs are reported in standard ways that ensure that the methods used 
were scientifically valid, authors are expected by many journals to submit their 
manuscripts pertaining to clinical trials in accordance with the guidance in the 
Consolidated Standards for Reporting Trials (CONSORT Statement) that is available 
from the website of the CONSORT group (http://www.consort-statement.org/). The 
CONSORT‘explanation and elaboration’ documents, checklists and flowdiagram of 
the trial’s recruitment and analysis plan, were developed using an evidence-based 
approach toimprove transparency of reporting of the methods used and the results of 
randomized controlled trials. The CONSORT statement was first published in 1996 
[25], and revised in 2001 [26], and in 2010 [27]. Various extensions that cover the 
reporting of cluster randomised trials [28], equivalence and non-inferiority trials [29], 
herbal interventions [30], the reporting of harms [31], pragmatic trials [32], and 
abstracts of RCTs [33], have also been published.  The 25 items in the revised 
CONSORT checklist weredesigned to help authors preparemanuscripts, and to help 
reviewers assess these manuscripts.One of the requirements of the Uniform 
Requirements for Manuscripts Submitted to Biomedical Journals (URMs) of the 
International Committee ofMedical Journal Editors (ICMJE) that are currently 
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endorsed by over 600 biomedical journals worldwide, is that reports of all RCTs 
conformto CONSORT.  However, the qualityof reporting of methods in RCTs from 
low- and middle-income countries, including India, continues to suboptimal [34-37]. 
A recent editorial in the Indian Journal of Psychiatry requires authors of RCTs to now 
conform to the CONSORT statement while submitting manuscripts [38] and it is 
hoped that the transparency of reporting will improve, as it has done with some other 
journals [39, 40]. 
The ICMJE URMs also require that ethical standards endorsed in the Declaration of 
Helsinki [8] be reported in trial publications pertaining to approval by ethics 
committees and obtaining informed consent, as well as to the prospective registration 
of clinical trials before recruitment of the first participant.  
Ethical issues associated with RCTs 
There are many ethical issues that may conflict with the desire of researchers, 
clinicians, and society with regard to the conduct of RCTs. The most controversial 
issues concern 1) the use of placebos and 2) the validity of informed consent obtained 
from vulnerable populations. 
The use of placebos in clinical trials 
A major ethical issue about RCTs concerns the need for the trial. The foundation of 
any clinical trial is the “principle of essentiality” emphasized by the Indian Council of 
Medical Research in its research ethics guidelines [9].  RCTs are ethically justified 
only when there is genuine uncertainty (or equipoise) about the usefulness of two 
treatments for a specific condition [41]. The use of placebos, when standard 
treatments exist, has been the subject of controversy for many years, since participants 
are seemingly being denied an effective intervention. Proponents of the use of 
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placebos argue that, except in life threatening situations, where the use of placebos are 
not justified, the use of placebos helps to determine the extent of improvement 
attributable to the intervention rather than due to expectations of benefit or harm or 
due to chance or to spontaneous fluctuations in the condition [1, 4, 41]. Counter-
arguments contend that any new intervention should be compared against standard 
treatment, since the use of placebos subject people to unethical harms caused by the 
continued disease process [6, 42]. 
Empirical evidence suggests that given the high placebo response rates in many 
psychiatric conditions (ranging from 15% to 50%, particularly in depression, and even 
in mania and to a lesser extent in schizophrenia), it may be misleading to make 
reliable conclusions of efficacy of a new intervention in the absence of a placebo 
comparator, even if compared with a supposedly effective treatments exist [4, 41]. In 
addition, psychiatric classification is based on a syndromic approach, driven by 
phenomenology and not informed by pharmaco-genetic or biophysical verification; 
blurred boundaries between disorder and distress result [41]. The interaction between 
the inexactness of the science and the fluctuating course of psychiatric disorders leads 
to a large proportion of patients in clinical practice and in trials experiencing a 
placebo effect [41].  
Critics of placebo-controlled trials often confuse internal validity (the extent to which 
the methods of the trial enable reliable interpretations of the effects of the 
intervention) and external validity (the ability to generalize the findings of particular 
trials). Placebo-controlled trials provide opportunities for high internal validity but 
may be difficult to apply to clinical practice; trials without a placebo control may 
more easily mimic what clinicians wish to know about the efficacy of the new 
intervention compared to standard treatment, but may provide unreliable impressions 
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of efficacy. Both forms of (and methods to evaluate) validity are important. 
Alternatively, three-armed trials that include a placebo comparison and the standard 
intervention could address both forms of validity simultaneously [41]. 
Empirical evidence indicates that participation in RCTs is not associated with worse 
outcomes than for those who refuse participation [43]; and may even result in better 
outcomes (including for those in placebo arms), due to the better care given to people 
in trials [44]. The Declaration of Helsinki permits the use of placebo when no 
established treatment exists; and when it is proven beyond doubt that the placebo 
would not cause the subject harm or put him at risk of irreversible nature; and when it 
is absolutely essential to test the efficacy and safety of the intervention against a 
placebo purely for established scientific and methodological reasons [8, 45].  The 
position of interventions that serve as the gold standard in psychiatric care and 
research has also undergone considerable change over the years for both 
antidepressant and antipsychotic medication, thereby ensuring the need to constantly 
re-evaluate the relative benefits and harms of interventions that are considered 
standard care [41].  
The US National Depressive and Manic-Depressive Association Consensus Statement 
on the use of placebos in clinical trials of mood disorders concluded that the placebo 
has a definite scientific role in mood disorder studies and that findings of equivalence 
between a new drug and standard treatment are not evidence of efficacy unless the 
new drug is also significantly more effective than placebo [46]. The situation is less 
clear in conditions such as schizophrenia where placebo responses are less dramatic 
than with depression, but do occur. The critical issue is whether the use of placebos 
has the potential to cause harm by deferring active treatment for the duration of the 
trial. There is no evidence to indicate that the short-term use of placebo does actually 
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cause harm, particularly if a) participants are closely monitored during the trial, b) are 
provided additional treatment to alleviate distressing symptoms, c) and are withdrawn 
after a reasonable time if they are not improved, or if they worsen, or experience 
adverse effects, or d) are permitted to withdraw consent due to any reason without any 
punitive consequences [47]. 
Issues related to informed consent and informed consent in vulnerable populations 
The Helsinki Declaration states that in any research on human beings, each potential 
subject must be adequately informed about the aims, methods, anticipated benefits 
and risks the research may entail [8]. There have been many concerns that the process 
of obtaining informed consent for RCTs, particularly in psychiatry, and particularly 
from low and middle income countries, is inadequate. The concerns centre around, a)  
the way consent is obtained, where the process of securing valid consent is reduced to 
a single event exemplified by the signing of the consent form and b) the possibility 
that true, voluntary and informed consent has not been obtained, nor is possible, in 
people with psychiatric disorders [6, 42, 48, 49]. These is particularly important in 
situations where research is combined with care so that participants have trust in their 
care providers, and believe they will be getting standard and personalized care; while 
parts of the treatment actually address issues relevant to research such as the use of 
placebos, wash-out periods, randomization, and blinding [41]. This reduced 
appreciation of the risks of research participation and the over-estimation of the 
benefits is called the “therapeutic misconception” [50]. The Declaration of Helsinki 
specifically addresses this issue and recommends that dealing with this not 
uncommon phenomenon requires consent forms to clearly define, and the consent 
process to clearly articulate, what constitutes research and what constitutes care [8]. 
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Empirical research indicates that older age, lower education, and worse health placed 
people at higher risk for holding a therapeutic misconception [50, 51].   
Traditionally, people with mental illness are presumed to have poor decisional ability 
and this is borne out by empirical evidence [52].  However, systematic evaluation, 
even in non-psychiatric populations and in high-income countries, has shown that 
participants in randomized trials recall information poorly, are not often aware that 
placebos form one arm of treatment, demonstrate inadequate comprehension of the 
process of chance in treatment allocation, understand and use only a proportion of 
what is presented in consent forms, do not really understand the issue of equipoise, 
and participate not for altruistic reasons but because they expect some improvement 
by participation [53]. Cognitive dysfunction and the symptoms associated with 
impaired decisional capacity are not unique to schizophrenia and may occur with 
many other forms of illness [54]. Furthermore, studies have also shown that many 
people with schizophrenia are able to give informed consent and retain related 
information across time [54]. There is also evidence that individuals who have 
schizophrenia and lack adequate decision-making capacity may improve significantly 
with educational remediation [52-55].    
The Declaration of Helsinki suggests that the individuals who are considered 
incompetent can be included in a research study provided it is proven that they are 
likely to benefit or even if they are unlikely to directly benefit then the intent of the 
said research is to promote the health of the population represented by the subject [8]. 
Also the research should entail only minimal risk and minimal discomfort to the 
vulnerable individual taking part in the study.  
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The Declaration also suggests proper justification of the research especially if it 
involves taking informed consent from people who are considered physically and 
mentally incompetent. The physical and mental condition of the subject should be the 
necessary characteristic that prevents such individuals from giving informed consent 
for research [8]. The Declaration also emphasizes that informed consent is not an all 
or none phenomenon; and that every effort should be made to gain consent from the 
individual or the legal representative to participate in and to remain in the research 
[8]. 
Thus, measures to protect vulnerable participants are needed to ensure that the 
methods of scientific research do not infringe on the rights of the mentally ill [56]. 
Adults who have psychiatric illness are often considered as requiring special 
consideration and protection as research participants. Institutional review boards often 
consider studies involving such persons using a different standard indicating that the 
concerns involving research with this population is different.  
However, there is a range of capacity based vulnerability among people with 
psychiatric illness. There may also be a variation in this capacity within psychiatric 
disorders, and with improvement in psychiatric disorders with treatment, or worsening 
of symptoms and cognitive abilities due to progression of the disease [51]. For the 
advancement of the ethics of scientific research and in psychiatry itself, it is important 
to know the factors that regulate participation into clinical trials in this particular 
population. 
Ethical principles and research in low income countries 
The cardinal principles that govern and shape ethical research practices hinge on the 
upholding of respect for the autonomy of the individual, exemplified in adherence to 
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maintaining confidentiality, truth telling, informed consent, and protection of 
vulnerable people; and a belief in beneficence and non-malfeasance, where the 
benefits and safety of the individual take precedence over scientific, financial or 
monetary advantage [10]. The cornerstones of this belief are the careful risk-benefit 
assessment that precedes and continues after ethical review, and the process of 
informed consent that views participants in research as partners to be fully informed, 
rather than research subjects [10]. The principle of justice is manifest in a fair 
selection of subjects so that all people who might benefit from the fruits of research 
are included. Thus, from this ethical standpoint, people with psychiatric disorders 
should not automatically, by virtue of their diagnosis, be excluded from participation 
in research [8]. This principle is also evident in the order of preference in the selection 
of classes of subjects, where vulnerable people are excluded from being research 
participants if the research question can be answered by including less vulnerable 
people. Thus adults are selected before children, non-pregnant women before 
pregnant women and people with reduced capacity to consent or prisoners may be 
involved as research subjects, if at all, only on certain conditions [9, 10]. 
These principles have gradually eroded over the years in all cultures due to the 
fragmentation of healthcare and the pressures of academia and industry. In developing 
countries, cultural issues have compounded these challenges of the traditional ethical 
principles, where belief in the collective good has been given precedence over 
individual autonomy due the structure of paternalistic family systems and health care 
systems; with vestiges of the Guru-sishya (chela) model of interaction permeating the 
doctor-patient relationship; rather than the contractual model envisaged by the 
informed consent process [57]. Further subverting the process are the low bargaining 
power the average individual; inadequate advocacy support; inequities in access to 
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healthcare of any quality, the costs and distances involved in accessing healthcare, 
etc., so that what may seem reasonable compensation for participation in research 
may be powerful inducements to participate [41, 47]. Evaluating the views of research 
participants from low income countries and from different socioeconomic 
backgrounds is therefore crucial to our understanding of the barriers and facilitators to 
trial participation. 
Assessing competence to consent in research 
Informed consent is "consent given voluntarily by a competent individual who has 
received the necessary information, has adequately understood the information and 
after considering theinformation, has arrived at a decision without having been 
subjected to coercion, undue influence orinducement, or intimidation" [9].Informed 
consent is based on the principle that competent individuals are entitled to choose 
freely whether to participate in research or not andprotects the individual's freedom of 
choice, respect for the individual's autonomy, and protects the individual’s rights [10]. 
Assessing competence to consent to participation is complex and often done 
arbitrarily. There have, therefore been calls by the US National Bioethics Advisory 
Commission for more formal assessments of the competence to consent to research 
among vulnerable subjects, particularly when research involves more than minimal 
risk; though this recommendation has also been criticized for requiring that all 
psychiatric patients be routinely evaluated formally for competence to consent to 
research, thereby presuming reduced capacity to participate in all people with 
psychiatric illness, unless otherwise proven [56].  
Competence is a legal construct, and only a court can decide whether a person is 
competent or incompetent. Assessment of capacity is undertaken by medical and 
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mental health professionals, and while referring to competence, it is the clinical 
assessment of capacity, not the legal determinations of competence, this is assessed. 
The capacity to understand and subsequently consent to research is particularly 
important for researchers, and this often raises problems since many people invited to 
participate inresearch have disorders affecting their cognitive and executive 
functioning. Specific populations like people with mental illness, AIDS patients, 
elderly persons with dementia and organic brain damage and people with substance 
use problems are ones whose capacity might be considered compromised; hence their 
informed consent process requires special focus. The US National Institute of Mental 
Health’s Epidemiological Catchment Area study (ECA) estimated that around 3% of 
the adult population have severe cognitive impairments, rendering them incompetent 
and eligible to participate in research; even though they may agree to participate [56]. 
It is therefore important to develop and use standard ways of assessing the capacity to 
consent to participate in research. 
Current standards [58] stipulate that assessment of competence (capacity to consent to 
research) should include evaluation of the person's ability to: 
1. Communicate choices: This is an ability to maintain and communicate stable 
choices, long enough for them to be implemented; 
2. Understand relevant information:  Persons who cannot understand what they have 
been told about a treatment are not competent to decide whether to accept or reject it; 
3. Appreciate one's situation and the consequences: Patients may comprehend certain 
information, but fail to grasp what it means for them. 
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4. Manipulate information rationally: This is the ability to use logical processes to 
compare the benefits and risks of various treatment options. 
These aspects are often considered by experiences researchers in clinical assessments 
of competence to consent, but it is important that they be routinely applied in a 
standard manner to be sure that people with psychiatric or other vulnerabilities who 
may readily consent, and superficially appear to have the capacity to consent, are 
actually competent to consent. 
The MacArthur Competence Assessment Tool for Clinical Research (MacCAT-CR) 
[59] is generally recognized as the best of currently available scales for formal 
assessmentof competence to provide valid informed consent to participate in research 
[51]. It isalso the most widely used in empirical research on consent capacity and 
adequate performance onthe MacCAT-CR was used in the CATIE trialas part of the 
criteria for independent consent [60]. It assesses competence on four subscales: 1) 
Understanding information, 2) appreciation of the significance of the information, 3) 
reasoning with the information, and 4) expressing a choice. Decisional capacity 
depends on the context and there is noparticular level of ability to determine adequate 
capacity in all circumstances [59]. Studies vary in level of risk and in the risk/benefit 
ratio. Total comprehension and appreciation along with high levels of reasoning 
abilities in patients with cognitive impairment might be considered unrealistic. An all 
or none phenomenon with rigid cut offs fails to take into account the possibility of 
different levels of competence that might be required depending on the nature of the 
project for which the consent is being sought. Thus what has been suggested is that 
instead of taking a fixed level of competence, a sliding scale would allow competence 
determinations to take in to account various factors which might influence a person’s 
ability to comprehend, appreciate, reason and express his willingness to agree or 
23 
 
disagree to participate in a research project. General consensus exists thatas the 
degree of risk increases, a higher level of capacity is desirable.  The MacCAT-CR has 
noestablished cut-score or algorithm for categorical determinations of capacity or 
incapacity; and it is recommended that the scores oncapacity assessment instruments, 
though helpful, should generally be supplemented with other important information, 
such as mental status and decision-making context [59]. The scores on the MacCAT-
CR have not been validated in the Indian context. 
Understanding trial participant’s perceptions about participation in clinical trials 
and of the facilitators and barriers to participation 
In recent years, the fraction of eligible patients who enrol in clinical trials has 
decreased worldwide [61]. This results in more time being required for completion of 
trials thus delaying important information and also in results being biased. 
Underpowered studies, at completion are unable to determine whether the treatment 
does more good than harm and hence raise ethical issues. Investigations of 
recruitment show that approximately only 50% of studies achieve their recruitment 
targets [62, 63]. One of the most important factors in the success of a trial is the 
willingness of the eligible participants to enrol into the trial. It is, therefore, important 
to explore and address the main factors affecting willingness to participate in trials. 
Understanding the barriers to participation can help to formulate interventions 
addressing those concerns. Identifying the factors facilitating trial participation can 
help in modifying trial designs to agree with participants’ wishes, particularly if these 
wishes were ascertained in advance.   
Attitudes towards participation in clinical trials 
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Attitudes of participants towards research in general have been studied across cultures 
and specific sub-populations. These studies indicate that clinical trials are viewed in 
general as being necessary and important, among participants and non-participants of 
these trials [61, 64-70]. Socio-demographic variables, psychological factors, monetary 
and health incentives were shown to affect willingness to participate in randomized 
controlled trial these studies. Although altruistic motives were given as the reason to 
participate, the decision to participate was also found to be associated with perceived 
health or monetary gains[69].  
Other factors that have been discussed in literature include the patient therapist 
relationship and the perceived trust the patient has in the doctor and the organization. 
Trials done among ethnic minorities specifically indicate that a sense of obligation to 
the medical personnel involved in recruitment and a sense of mistrust were significant 
factors affecting the participation in trials [69, 70]. 
Barriers and facilitators to participation in clinical trials  
An increasing number of studies have assessed barriers to participation in clinical 
trials; of these only the findings most relevant to this study are presented here. A 
meta-analysis of all studies evaluating the factors and barriers, from the perspective of 
potential Indian participants, contributing to their participation in clinical trials, 
identified through systematic searches of published literature, six qualitative studies 
and one survey that evaluated factors affecting the participation of Indian subjects 
[69]. The results showed that personal health benefits, altruism, trust in physicians, 
earning extra income from participation, detailed knowledge provided by the 
informed consent process and the methods used for motivating participants were the 
factors that increased participation; while mistrust of the organisation conducting the 
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trial, concerns about the efficacy and safety of trials, other psychological reasons, the 
burden posed by the methods used in the trial, fears about the confidentiality, issues 
related to dependency, and the use of language that was difficult to understand, were 
considered as barriers to participation [69]. In a quasi-experimental study involving 
vignettes presented to 1,277 Swiss patients, a higher willingness to participate was 
found when a new drug had no side effects, no additional visits were required, the 
information given balanced benefits and harms, the results were in the public domain, 
and the project was approved by a research ethics committee. In contrast in this study, 
destruction of blood samples at the end of the project, the use of placebo controls, and 
random allocation to study arms were associated with a lower likelihood of 
participation. Other variables such as funding sources, financial rewards, the need to 
complete a questionnaire, and the clinical need versus the potential economic purpose 
of the study did not influence willingness to participate [71]. In another study done on 
Indian patients attending a government tertiary care centre, 70% of 102 adults 
approached to participate in a ‘mock trial’ refused consent to participate [72]. More 
females than males refused participation. The reasons for refusing to participate 
included fear of giving more blood, reluctance to take a new drug, inability to make 
independent decisions, fear of tests, feeling too sick to participate, and not wanting to 
interrupt treatment [72]. Among those who agreed to participate, wanting to help the 
medical community, trust in their doctors to do only good, and wanting relief from 
pain were the most important reasons offered by participants [72]. The decision to 
participate was not influenced by the amount of information provided in the informed 
consent form [72]. This study highlighted two major aspects of recruitment to clinical 
trials in India. The first is that large numbers of patients may actually refuse to 
participate in clinical trials, but since this trial was not designed to test actual 
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recruitment and was conducted in a government hospital where costs were largely 
borne by the provider, it is unclear if access to care that is dependent on trial 
participation will change these estimates among those who cannot access routine 
clinical care due to financial constraints. Secondly, it highlighted that consent to 
participate may not be influenced by the amount of information provided in consent 
forms but by the other factors associated with participation such as the desire for 
personal benefit, altruism, and trust in their doctors. Thus, it may be that many 
patients who consent to participate in clinical trials do not actually understand the 
contents of consent forms adequately enough to provide what would be considered 
valid and informed consent. Since a placebo condition was not part of this study, it is 
unclear if Indian patients would subscribe to the use of placebos.  
Consent forms are typically not be understood by average persons because they are 
too long, too complex, incomprehensible, and often written by lawyers than educators 
[53].  Conversation in securing informed consent is more reliable when the physician 
can assess the actual understanding of patients and evaluate their legitimate or 
irrational concerns. However, the information sheet and informed consent form are 
necessary in clinical research to ensure that the information provided was uniform and 
reasonably comprehensive.  
Empirical research with psychiatric patients has demonstrated that patients are able to 
understand and use only a small proportion of information provided in consent forms, 
and this is especially true with depressed patients and those with schizophrenia [53, 
73]. However, conflicting findings have emerged from Indian studies.  
In a postal survey of 3622 physicians, several constraints in obtaining informing 
consent were noted, particularly concerning illiteracy of patients. In this survey, the 
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opinions on the amount of information to be provided to obtain informed consent 
revealed that informed consent procedures were far from ideal [74]. Structured 
interviews with a sample of subjects who were users of health care revealed that the 
majority was dissatisfied with many aspects of the physician- patient encounter 
including the amount of information provided [75]. Physicians interviewed felt more 
frequently than patients did that illiteracy was an impediment to obtaining informed 
consent. This study found that patients often felt that information about the nature of 
investigations and prognosis need not be routinely revealed [75]. 
A systematic study of informed consent for a drug trial showed that the majority of 
Indian patients showed adequate comprehension of issues involved and exercised a 
clear choice. The study stressed the need for all physicians to provide adequate 
information about research, though the form of presentation itself needs to be 
simplified [76].  
In a study of 100 consecutive patients in a tertiary care hospital in India undergoing 
gastrointestinal surgery to test understanding and retention of information provided 
about the procedure, the majority of patients reported that they appreciated being 
given adequate information. While older, less educated and poorer patients performed 
worse than younger, educated patients, 70% recalled salient information regarding the 
procedure [77]. However, qualitative study of people who had undergone ECT and 
their relatives revealed that many patients felt the information provided was 
inadequate; some felt coerced into accepting treatment and though all relatives and 
some patients had signed the consent forms, many did not recall the information 
provided. This opinion was influenced by their mental state before treatment as those 
who were voluntary admissions were more likely to be satisfied with the consent than 
thos who were admitted involuntarily [78]. 
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Very few Indian studies have assessed ways to improve the process of obtaining 
consent. A randomized controlled trial to assess whether participants in a community-
based nutritional trial who received group counselling prior to administration of 
informed consent understood the key components of the study and the consent better 
than those who received individual counselling; based on the hypothesis that group 
counselling would foster discussion among potential participants and enhance their 
understanding of the informed consent. No differences were seen between the groups 
in terms of comprehension of key elements of informed consent and randomization, 
although all participants were aware of the details of the intervention and that they 
were involved in research. Many reported that one of the main reasons for their 
participation was better access to affordable healthcare that participation provided, 
compared to usual care [79]. 
The importance of family members in providing consent was highlighted in some 
Indian studies [72]. Family members in  Indiatend to have a protective attitude 
towards their relatives and often do not wish for them to be provided too much 
information or information that is considered upsetting. In a study assessing the 
attitudes of depressed patients and their relatives towards informed consent for ECT, 
the overwhelming majority of the patients and their relatives wished to be given 
information about the ensuing treatment procedure, as well as illness details and 
prognosis, and felt they could understand the information if presented in a simplified 
and clear manner. The majority felt that their consent for treatment was necessary; 
however they wished that their doctors be the final decision-makers regarding the 
need for ECT. Psychotic symptoms and past exposure to ECT differentially affected 
these attitudes. These attitudes did not change significantly as a result of treatment. 
While patients’ attitudes did not significantly differ from relatives’ attitudes in 
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general, significantly more relatives felt information should be withheld from patients 
[80]. The last feature is a fairly common finding in clinical practice and suggests the 
need to involve relatives in treatment decision making as well as educating them on 
the need to divulge information to patients in the interests of ensuring treatment 
compliance [81]. 
Involving patients and relatives in designing research 
It is widely accepted in many developing countries that involving service users in the 
design of research will result in more relevant researchquestions being developed, a 
higher level of trial recruitment and participation, better methods being used, better 
design of information to be provided to patients, and better interpretation of the 
findings from these studies [82, 83] . Most clinicians and researchers as well as trial 
participants welcomed this greater involvement [83]. However, it is unclear if Indian 
researchers and Indian trial participants would hold similar views given the 
paternalistic nature of the doctor-patient relationship traditionally seen in India. 
Prospective ascertainment of the views of potential trail participants 
Prospective preference assessment (PPA) was proposed as a method to increase 
participant recruitment in clinical trials by evaluating potential trial participants' 
motivations for participation, and their concerns about participation in a planned 
trial,before formal recruitmentin clinical trials [84].This method would also be able to 
identify those patients to whom a trial's results may be relevant, and would also 
protect the interests of participants [84]. The method involves presenting a 
hypothetical trial design and using both quantitative and qualitative measures to elicit 
willingness to participate in the trial along with the motivations and concerns 
participants have about trial participation [84-86]. Such interviews also include 
demographic and disease-specific data to investigate the ways in which people who 
express willingness to participate differ from those who do not.  
This approach has other uses too, as it can be used to test and enhance understanding 
by potential participants of the key concepts of the trial(apart from the motivations 
and concerns regarding potential participation), and can also be used to evaluate 
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changes in understanding following educational interventions. Only 12(6.3%) of one 
hundred ninety patients with schizophrenia recruited in a study using this method 
were assessed to have understood all key trial-related concepts at baseline, though this 
proportion increased significantly after a brief educational intervention [85]. In this 
study, younger people and those with higher levels of education were significantly 
more likely to have better understanding of the prosed methods. Here too, the main 
reasons cited for wishing to participate in were personal medical benefits and 
altruistic desire to help others; while concerns regarding the safety of the trial 
medication were also expressed by the majority [85]. The PPA method was also used 
effectively in a vaccine trial to predict and improve enrolment rates [11], and to 
identify subgroups of potential participants who would need additional education to 
increase recruitment in order to ensure that participants in a trial of dialysis were more 
representative of those who are treated by dialysis in clinical care [86]. 
Since in India, family members are often central to decisions involving participation 
of patients in clinical research, the views of the key family member of participating 
patients could also be ascertained using the same methods. 
Issues related to the methods of assessing barriers and facilitators and the 
prospective assessment method 
The PPA method involves presenting a hypothetical trial design and using both 
quantitative and qualitative measures to elicit willingness to participate in the trial 
along with the motivations and concerns participants have about trial participation. 
Such interviews also include demographic and disease-specific data to investigate the 




Hypothetical designs may not actually predict actual recruitment to a trial, though the 
indications are that there is a correlation between expressed willingness to participate 
and eventual recruitment [11, 85, 86]. The quantitative part of such studies provide 
estimates of frequency of willingness and the factors that differ between those who 
consent and those who do not; but more important is the qualitative part of such 
approaches that provide in-evaluations of the concerns, barriers and facilitators to 
participation. Such qualitative approaches use in-depth interviews of individuals, 
using a semi-structured approach followed by open ended and probing questions, 
often recorded verbatim and the transcripts analysed using thematic analyses [87]. 
One of these methods used to analyse qualitative data is the “Grounded Theory” 
framework [88, 89]. Grounded theory is as an inductive method for qualitative 
analysis that generates theory from data. The central idea is that it is grounded in, and 
remains connected to, the data, and in the understanding and experiences that people 
have about a phenomenon [88, 89].  An inductive method is one where the theory 
emerges from the data, in contrast to deductive theory, where the researcher starts 
with an abstract idea or theory and then tests propositions related to the theory. The 
greatest strength of grounded theory is that it goes beyond mere description and 
provides a method of developing an explanatory model that accounts for change and 
variation in human behaviour [88, 89]. 
Qualitative research also needs to follow reporting standards as much as RCTs are 
expected to follow the CONSORT statement. While no universally approved 
reporting standard exists for qualitative research, one such standard is the 




Materials and Methods 
Study design 
This cross-sectional study used quantitative and qualitative methods to evaluate the 
attitudes of participants (patients and relatives separately) towards participation in 
clinical trials and their willingness to participate in a hypothetical trial and an 
extension of this hypothetical trial.  
A quantitative survey using a semi-structured questionnaire assessed their attitudes 
towards participation in research based on the information provided in an information 
sheet inviting them to participate in this study that also explained the rationale and the 
methods of RCTs and the information sheets of the hypothetical trial. Qualitative 
methods were used to evaluate recorded and transcribed verbatim responses,  
clarifications and concerns to this information, and to evaluate their comprehension of 
the information sheets for  the hypothetical RCT and an extension; as well as to 
evaluate the reasons they advanced as factors that might increase or decrease their 
chances of participation. The data were also analysed using quantitative and 
qualitative methods.  
Setting 
The study was conducted at the department of psychiatry, of a teaching general 
hospital in South India.  The department has four units in all, with two units catering 
to adult psychiatry cases, one unit concerned with rehabilitative psychiatry and one 
unit catering to child and adolescent psychiatry.  The in-patient services of the 
department are geared towards family involvement in care and include a 120 bedded 
hospital where patients stay with their family members for treatment for a variable 
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period of time; the average period being four to six weeks. The department caters to a 
variety of problems ranging from psychosis, neurosis, alcohol and substance related 
problems, mood disorders to adjustment, personality and relationship problems. 
In-patient accommodation is of three types, depending on the socioeconomic status 
and financial resources of patients.  The ‘Annexe” provides dormitoriesfor four to six 
patients each and their attending relatives. The charges are nominal and concessional 
or free care is granted by the treating team for economically disadvantaged people 
admitted here. There are 20 beds in this category for adult patients. Single family 
units consisting of a room with a semi-detached toilet and kitchen that offer more 
privacy and space are available in the ‘Low-cost private wards’ for paying patients. 
There are 37 beds in this category for adult patients. The ‘Private’ ward consists of 18 
single rooms (air-conditioned and non-air-conditioned) for adult patients, that are self-
contained units consisting of a bed-room with an attached enclosed courtyard, dining 
space, bathroom, and kitchen. 
The department is part of a teaching general hospital but is situated in part of the 
residential campus of the institution, and does not have a closed ward, though 
disturbed patients may be restrained in an open high-dependency ward with relatives 
in attendance and 24-hour nursing cover and doctors on call, and when less disturbed 
may be shifted to one of 12 ‘Acute care rooms’. Involuntary patients are admitted 
under the provisions of the Mental Health Act of 1987 [91]. 
All in-patients (and out-patients) are worked up by post-graduate registrars who 
discuss cases with consultant psychiatrists, or are worked up directly by consultants. 
In-patients are provided care by their allocated treating doctors, and a 
multidisciplinary team of psychiatrists, nurses, occupational therapists, and social 
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workers, and the emphasis is on humane and collaborative treatment, using an eclectic 
mixture of psychotherapy, education, support, occupational therapy, and medication. 
The primary therapist and the supervising consultant invariably develop a good 
rapport with the patient and relatives in view of the multiple sessions and time spent 
in clarification of diagnosis and discussion of management strategies that include 
pharmacological and non-pharmacological therapies. 
Setting for data collection for the study 
One of the assessment rooms in the hospital was chosen for conducting the 
interviews. Data collection was done in this room taking care to ensure it was quiet 
with minimal intrusions, and shielded from noise to ensure good audio-quality of the 
recorded interviews. 
The patient and relative were initially met in the ward and if they agreed to 
participate, or required further information, they were later invited the interview room 
for the interviews. During the initial session, which was focussed on rapport building, 
both patient and the key relative were seen together, and subsequently they were 
interviewed separately. Non-participants were not present during the interviews.   
The interviews for each participant were conducted in multiple sessions over many 
days as per the convenience of the participants. As the inpatient treatment programme 
includes occupational therapy and psychotherapy sessions with the individual 
therapists, care was taken not to interrupt their schedules as far as possible. The 
session for rapport building was not timed or recorded. It was understood from the 
pilot study that a good rapport was crucial for improving the quality of the interviews 
and hence these sessions were held prior to the starting of the interviews on separate 
days. The participants were informed regarding the credentials of the interviewers and 
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it was mentioned that the study was being done as a part of the training for the 
primary investigator’s degree in psychiatry. 
Participants 
Participants were recruited from the adult units of the inpatient services of the 
department from July 2012 to October 2012. All patients admitted into the wards, 
satisfying the inclusion and exclusion criteria were eligible to become participants. 
Inclusion criteria 
1. Adult patients (18-65 years) admitted to the hospital for at least one week who 
consented to participate in this study with: 
a. A clinical diagnosis of ICD- 10 Major Depressive Disorder-single 
episode or Recurrent Depressive disorder (with or without psychotic 
symptoms), Bipolar Affective Disorder (with or without psychotic symptoms), 
Manic Episode, Schizophrenia, Schizo-affective Disorder, Obsessive 
Compulsive Disorder, Generalized or Situational Anxiety Disorders, Phobic 
Disorders, Somatoform disorders 
b. Clinical Global Impression Severity [92] score of 4 (moderately ill) or 
more 
2. One key relative/care-giver, identified by a consenting patient with psychiatric 
illness, who provides informed consent to participate. 






1. ICD 10 diagnosis of Substance use disorder, or Organic disorder, or Disorder 
due to brain damage or dysfunction, primary diagnosis of Personality 
Disorder, Adjustment Disorder 
2. Acutely ill patients 
a. Requiring admission into the acute care rooms 
b. Who would require periodic monitoring in the acute care room in view 
of risk of harm to self or others 
3. Patients and /or relatives who do not consent 
4. Patient considered by treating psychiatrist as not suitable for participation in 
this study for any reason 
5. Key relatives clinically diagnosed to have a current psychiatric disorder with 
clinical active symptoms of any degree of severity 
Sampling methods 
Consecutive inpatients were planned to be approached, but purposive and theory-
based sampling was also employed to obtain adequate representativeness of the 
sample by ensuring that at least half the patients have a psychotic condition and the 
remainder a non-psychotic condition. This also helped to ensure that female patients, 
and those with lower levels of literacy, were also adequately represented. 
Method of approach 
A face-to-face method was employed taking time to develop rapport while informing 
potential participants of the study and inviting their participation while giving them 
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the informed consent form for the study. Following the rapport building session the 
interviews were recorded on a voice recorder after getting consent for participation. 
Sample size 
Thirty in patients and their relatives were planned to be recruited yielding a total 
sample of 60 participants. Since this is an exploratory study with in-depth analysis of 
attitudes and views, formal sample size determinations were not done. The intention 
was not for the sample to be representative of participants’ views across India, but 
rather to achieve a saturation point of ideas and views.  
Preparation of study materials 
1. The information sheet regarding the nature of the study and the issues related to 
the methods used in RCTs were prepared in order to adequately inform 
participants of the details of the study and to aid their comprehension; and this 
information included the following elements: 
A. An invitation to participate in a study approved by the Institutional Review 
Board of the Institution and the purpose of the study; 
B. A statement that taking part in this study does not form any part of the 
treatment being provided at this hospital, and the decision to take part or not 
take part in this study will not affect the treatment provided at this hospital. 
C. The nature of research used to study new medicines and the issues related to 
the methods of RCTs that are aimed at minimising bias and confounders and 
the ethical issues these methods entail; 
D. Information about what they would have to do if they decided to participate, 
including the a) fact that they would be invited to provide responses to 
questions about their opinions about the nature of RCTs; b) they would be 
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invited to participate in an imaginary trial (and an extension), for which they 
would be provided details in an information sheet in the language of their 
preference (English or Tamil) and have this form explained to them, if needed; 
c) their comprehension of the details in the information sheet would be 
assessed; d) their responses during the interview would be recorded for 
transcription and analyses; e) an independent interview would be conducted 
within 48 hours or at the earliest by a consultant psychiatrist to assess their 
capacity to consent. 
E. A statement of the extent of their responsibilities; 
F. The potential benefits of participation; 
G. The voluntary nature of their participation, and the possibility of withdrawal 
without any adverse consequences even after consent is given; 
H. Financial disclosures about funding for this study; 
I. Details about confidentiality and disclosure of the results of the study 
J. Contact information of investigators.   
The information sheet and informed consent forms were pilot tested and revised and 
the final version is provided in Appendix 1a. These forms were translated into Tamil 
and back-translated into English to ensure the accuracy of the translation; and the 
Tamil version is also provided in Appendix 1b. 
2. Demographic data and illness details: Details of socio-economic status, and of the 
illness and included the following: 





• Socioeconomic status as decided by the room category during 
 admission 
• Educational status  
• Literacy level  
• Occupation 
• Relationship to patient/key relative 
b. Clinical variables (for patients): 
• ICD 10 diagnosis 
• Duration of illness 
• Duration of current episode/exacerbation 
• Presence of active psychotic symptoms (Delusions/hallucinations) in 
 the past 24 hours: Present/Probable/Unclear/Absent 
• Current medication (antidepressant and dose/ antipsychotic and 
 dose/anxiolytic and dose/ anticholinergic and dose/ mood stabiliser and 
 dose/ other medication and dose 
• Presence of treatment non-response in past 
• Nature of the consent given for admission into hospital 
 (voluntary/involuntary) 
• Scoring on the Clinical Global Impression scale- severity 
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• Clinical assessment of grades of insight 
c. Clinical variables (for key relatives): 
• History of psychiatric illness and details 
• Current evidence of psychiatric illness on clinical interview 
• Any current medication 
The data collection form used is provided in Appendix 2. 
3. The attitudes to research questionnaire: This questionnaire was prepared based on 
the findings of the literature review and from clinical experience with Indian 
subjects and consisted of 20 questions with responses scored on  a Likert-type 
scale ranging from Strongly agree/ Agree/ Do not know/ Disagree/ Strongly 
disagree and included the responses of Did not understand/ Other response. The 
20 questions covered ten major themes.  They were: 
a) The necessity of RCTs as perceived by the participants (question 1) 
b) The reasons for participation in RCTs (questions, 2, 4, 6, 11),  
c) Doctors motives in conducting RCTs (questions 3, 5, 7),  
d) Problems faced by patients in RCTs (questions 8, 12), 
e) Disadvantages of RCTs (questions 9, 10, 14), 
f) Opinions regarding the key elements of RCTs (randomization, blinding, 
informed consent) (questions 15, 16, 17), 
g) Involving patients in designing trials (question 18), 
h) Participation in trials as a duty of every individual (question 19),  
i) Willingness to participate in placebo controlled trials (question 20), 
j) Decision to participate as a family decision (question 13). 
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This questionnaire is provided in Appendix 3. 
4. The information regarding the hypothetical trial was designed to contain the 
following elements, in addition to essential elements of informed consent 
stipulated in the ICMR ethical guidelines [9]:  
A. An invitation to participate in an imaginary trial and the purpose of this 
exercise 
B. A wash out period from existing medications if they decided to participate, 
C. A new study medicine that will be compared to a dummy medicine; 
D. The supposed effects of the new medicine on stress-related symptoms, and the 
possible adverse effects; 
E. The fact that participants will be randomised to either the new medicine or to 
placebo; 
F. The reasons for the randomised design; 
G. The fact that neither participants or investigators will be able to know what 
treatment was being provided due to the blinding and allocation concealment, 
and the need for this; 
H. The 8-week duration of the trial and the weekly assessments of symptoms and 
adverse events 
I. The need to be hospitalised for the first four weeks at least; 
J. The fact that trial medicines would be provided free and costs of treating any 
adverse events would also be free; 
K. The fact that sedatives and any other treatment needed for symptom relief 
would be provided; 
L. The amount of reimbursement for study related visits 
M. Details about confidentiality 
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N. Information about post-trial access to medicines and further treatment 
These information sheets and informed consent forms were also pilot tested, 
translated into Tamil, back-translated into English and is provided in Appendix 4a. 
5. Assessment of comprehension regarding information provided for the hypothetical 
trial comparing a new drug versus placebo. A questionnaire providing 10 
statements to be answered True / False / Unsure / Do not know was prepared to 
test the information provided and included assessments about their understanding 
regarding randomisation, blinding, placebos, compensation etc, that would be 
used in the trial. This comprehension assessment questionnaire is provided in 
Appendix 4b. 
6. Qualitative interviews regarding the hypothetical trial: During the audio-recorded 
interview, participants were asked if they would be willing to participate in the 
hypothetical trial and the reasons for participation or for declining to participate. 
A set of probe questions that were to be used to facilitate this interview were 
designed to ensure that participants freely expressed their opinions; and these 
questions are provided in Appendix 4c.. 
7. Information sheet regarding the extension to the hypothetical trial. Participants 
were also asked to participate in an extension to the hypothetical RCT. The 
information sheet for this extension included information about the hypothetical 
trial but included additional elements designed to add to study burdens, and 
included blood tests, an ECG and an EEG. No wash-out period was used in this 
extension. The information sheet for this extension was also pilot-tested and 
revised; translated to Tamil and back-translated to English. The information sheet 
and informed consent form for this extension are provided in Appendix 4d. 
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8. Assessment of comprehension about information regarding the extension trial. 
Five questions scored as in the previous questionnaire assessing comprehension 
were designed to assess the comprehension of the information about the extension. 
These questions are provided in Appendix 4e. 
9. Qualitative interviews regarding the extension to the hypothetical trial. The open 
ended questions designed to probe participants responses during audio-recorded 
interviews regarding their willingness to participate in the extension trial are 
provided in Appendix 4f.  
10. Assessments of competence (capacity) to provide valid consent to participate: The 
primary assessment of capacity to consent was done during clinical interviews and 
included assessments of mental state, degree of cooperation, ability to 
comprehend the information provided and an overall assessment during the course 
of the interview about how decisionally-impaired, psychotic, or lacking in insight 
participants were. A sub-set of participants were independently interviewed using 
the MaCAT-CR that was adapted to assess the information provided in the 
information sheets and additional probe questions added. The MaCAT-CR used 
for this study is provided in Appendix 5. 
Ethical issues 
All participants were informed about the voluntary nature of their participation and 
their right to decline. The methods, information sheets used, and the full protocol of 
the study were approved by the Institutional Review Board (Research and Ethics 
Committees) of the Christian Medical College, Vellore. Data are presented to 
maintain the anonymity of the individual participants. Quotations used in the reports 
do not include any information that can possibly identify the participant. 
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Study conduct and Data collection 
Step 1: 
Patients admitted to the hospital, meeting the inclusion and exclusion criteria were 
enrolled into the study after obtaining their written, informed consent. The 
information sheet and consent form for participation in the study is provided in 
Appendix 1a and 1b.Consent was sought for the interviews, for audio-recordings of 
the same, and for the assessment of competence using the MacCAT-CR.  
Step 2: 
Demographic and clinical data was collected in to a data extraction sheet. Information 
was obtained from the primary therapist, medical records and the patients for the 
same. The data collection sheet is provided in Appendix 2. This time was also used to 
build rapport with the patient and the key relative.  
Step 3: 
All patients were assessed for severity of illness using the Clinical Global Impression 
(CGI) [92]. The CGI scale is a brief assessment tool in psychiatry comprising three 
items measuring illness severity, global improvement and therapeutic response. Each 
component is rated separately and the instrument does not yield a global score. For 
this study participating patients were rated only on the Clinical Global Impression 
scale Severity item, which asks the clinician the question of how mentally ill the 
patient is at the time of assessment, rated on a seven point scale: 
1=normal, not at all ill 
2=borderline mentally ill 
3=mildly ill 




6=severely ill  
7=among the most extremely ill patients. 
 The rating is based upon observed and reported symptoms, behavior, and function in 
the seven days prior to assessment. For the purposes of the study this assessment was 
made for the preceding 24 hour period.  
Step 4:   
A clinical assessment of competence to provide consent of patients and their key 
relatives was made by the primary investigator before and after the completion of the 
interviews. Patients, who were assessed as not competent, were approached on two 
separate occasions at weekly intervals to re-assess competence. One key relative was 
recruited at the initial assessment for the attitudes to research questionnaire, if consent 
was obtained. The MacCAT-CR was administered to both members at the final 
assessment point.  
Step 5:  
Administration of the attitudes to participation in clinical trials questionnaire: This 
structured questionnaire was given to literate participants to read and was read out 
loud to non-literate participants. Responses were recorded by the research clinician, 
after verifying comprehension. This questionnaire assessed the attitudes of 
participants toward research participation in general and to the specific components of 
the methods used in RCTs (Appendix 3). 
Step 6: 
Invitation to participate in a hypothetical RCT: The information sheet for the 
hypothetical RCT (Appendix 4a) was administered to participants as in step 5. 
Opportunities were provided to seek clarification regarding the contents of this 




Administration of the questionnaire assessing comprehension of the information 
administered in the information sheet of the hypothetical RCT (Appendix 4b) and the 
proportion expressing willingness to consent was noted. The key-relative’s 
willingness for the patient to participate was assessed.  Reasons for consenting or 
declining were explored using open ended questions and probes and participants were 
facilitated to express their opinions and concerns(Appendix 4c). 
Step 8: 
Those who consented and those who refused to participate in the hypothetical trial 
were presented, an additional extension of the trial (Appendix 4d) that posed 
differences in interventions and increasing levels of inconvenience. The actions 
described in Step 7 were repeated for this extension as for the main hypothetical trial, 
assessing comprehension (Appendix 4e) using open-ended questions and clarifying 
probes (Appendix 4f).   
Step 9: 
The MacCAT-CR (Appendix 5)was administered on a separate occasion within 48 
hours of the initial evaluation after re-affirming consent obtained earlier by the 
primary investigator. The assessments were performed and scored by the co-
investigator (a consultant psychiatrist) using the standard procedures described in the 
manual accompanying the tool. 
All the above assessments were audio-recorded (with the consent of participants) and 






Data handling and analyses 
Quantitative variables 
Socio-demographic and illness variables were summarised using frequencies and their 
distributions (if possible). The frequencies and nature of responses to the attitudes to 
research in general and the specific components of RCTs were calculated in patients 
and relatives. The proportion of participants who demonstrated adequate 
comprehension of the information for the hypothetical RCT was assessed. The 
proportions of participants that expressed willingness to participate and that refused 
participation in the hypothetical RCTs were determined.The proportion of participants 
who endorsed favourable views to RCTs and who also express willingness to 
participate in the hypothetical trials was assessed. 
The proportion of participants considered to have adequate capacity on clinical 
assessment was further evaluated to evaluate the proportion assessed as adequate on 
the MacCAT-CR; on all the domains (Understanding information, appreciation of the 
significance of the information, reasoning with the information, and expressing a 
choice).The performance of participants’ competence was evaluated using stringent 
standards (adequate on all domains); intermediate standards (adequate on three 
domains: Understanding information, appreciation of the significance of the 
information, reasoning with the information) and the least stringent criteria 
(Understanding information). The proportion of participants considered to have 
adequate capacity were also evaluated using scores that were 50% of the maximum 
possible for the above criteria. 
Formal statistical analyses of differences in responses in relatives and patients and 




Qualitative data and analyses 
Data analysis on the transcripts of the audio-recordings of the interviews were 
undertaken inductively and iteratively based on the principles of Grounded Theory. 
The transcripts of interviews were checked for accuracy and were read by the 
investigators to identify commonly expressed themes and sub-themes.  Based on this 
emerging themes and sub-themes a study framework was developed, where themes 
are coded because of their characteristics as being explicit, strongly held, reflective of 
good research ethics and for highlighting participant’s concernsand increasing their 
comfort with trial participation. Illustrative quotations were selected for emerging 
themes and findings and were presented without being linked to participants in order 






A sample of 30 patients and relatives were planned to be recruited. However due to 
time constraints, and lack of sufficient patients who fulfilled all eligibility criteria, the 
sample size planned could not be attained.  
During the period of the study, 20 patients and their relatives (40 eligible participants) 
were found eligible to participate according to the inclusion and exclusion criteria. Of 
these, eight patients and relatives (16) refused to participate in the study.  
Of the 12 patients and their relatives (24 participants) who initially consented, three 
patients refused to give consent.  
The reasons for refusal to participate were sought from all three. A voice recording of 
the interview exploring the reasons for refusal could be obtainedonly for one patient. 
The details regarding refusal were recorded as part of field notes for the other two 
participants. One patient and relative had given consent but was unable to attend 
interviews due to inconveniences and practical difficulties in coming for the sessions.  
Figure 1 describes the flow of participants into the various components of this study. 
Of the 24 participants who consented, not all completed all steps of the study as some 
refused to continue to participate at various time points or could not find time amidst 
their treatment schedules to complete assessments. One patient was assessed as not 
competent to provide informed consent during clinical assessments during the first 
interview; another patient was found to have clinically worsened during a subsequent 
interview and was declared as lacking capacity to consent and hence was withdrawn 











Socio-demographic details and illness details (of patients) 
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Of the 20 patients who were eligible to participate (Figure 1), 10 patients were 
voluntary admissions, while the other 10 were admitted at the request of their relatives 
under the provisions of the Mental Health Act. Sixof the patients were admitted in the 
private wards, 10 were admitted in the low cost private wards and four were admitted 
in the annexe dormitories. The mean age of the participants was 28 years (SD 8 years; 
range 18 to 47 years). There were equal numbers of males (10) and females (10) 
among the eligible participants.  
Of the 12 patients who consented to participate (6 voluntary admissions), seven were 
females. Four were admitted in the private wards, five in the low cost private wards, 
and three in the annexe dormitories. Their mean age (SD) was 25 (6) years and their 
age ranged from 18 years to 38 years. Six of the 12 consenting patients (50%) and 6 
of the 8 non-consenting patients (75%) were graduates, while five of the consenting 
patients (41%) and 1 (13%) of the non-consenting patients had a primary or secondary 
school education, and one in each group were diploma holders. Six of the 12 (50%) 
consenting patients had a CGI severity score indicating a moderate level of severity 
while the others were markedly ill; five (63%) of the non-consenting patients were 
moderately ill, two (25%) were markedly ill, and one (12%) was severely ill.  
Five of the 12 consenting relatives were male (three were fathers of patients, one a 
grandfather, and one a husband). The seven female relatives were mothers of 
consenting patients. Six were graduates, five had some years of schooling (primary 
school = 3,   secondary school = 2) and one was a diploma holder. Four of the 
consenting patients and relatives read and spoke only Tamil.  Seven of the patients 
had a diagnosis (ICD 10) of schizophrenia, one had a delusional disorder, one had 
hypomania, one had mania without psychotic symptoms, Three of the 12 patients had 
very poor insight and two of them were subsequently deemed as lacking the capacity 
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to consent due to worsening of psychotic symptoms, two had recurrent depressive 
disorder (one with psychotic symptoms), and one had a dissociative motor disorder.  
Attitudes to clinical research 
The results of the 20-item questionnaire assessing the attitudes of patients (N = 8) and 
relatives (N = 10) towards participation in clinical trials are shown in Table 1, 
grouped under the 9 themes and sub-themes. The quantitative results were 
supplemented by qualitative responses obtained by participants during interviews. 
All the patients and relatives agreed that it was necessary to test new drugs 
scientifically before using them in clinical practice (Table 1). For example, one 
participant stated, ““I agree strongly regarding the clinical tests on patients. Without 
strong studies, it cannot be used in general manner.” However, this general 
endorsement need not necessarily imply that all would endorse participation in 
clinical trials. One relative stated, “What I perceived is that it is simply a theoretical 
study and we want to talk about these things, but actually I do not intend my patient to 
be given any new medication even if it is dummy ones.” 
Regarding reasons why patients participate in clinical trials, all patients and 
participants felt that for patients, faith in the doctor and the institution are the most 
important motivating factors behind deciding to take part in a clinical trial. Altruism 
as a motive for participation was expressed by all the relatives and 75% of patients 
who felt that patients participate in research to help in reducing human suffering as a 
whole.  However, half the patients agreed with the statement that patients participate 
in research trials because they expect to get personal health care and health benefits, 
while half the relatives disagreed with this notion. More than a third of relatives and 
more than half the patients disagreed with the statement that patients participate in 
research trials mainly because they expect to get monetary benefits.  
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Qualitative responses added other views for why patients may wish to participate in 
clinical trials. One person felt that participation depends on the type of medication 
being tested, “..It also depends on the intensity or like what type of medicine and what 
are the risks involved in that, so if it is a normal medicine like suppose paracetamol, 
maybe someone wants to try something similar to it, maybe nobody will object to it 
because that will not cause harm, but if it is such a medicine, which can harm in some 
other way then a patient can resist,….He will be a little hesitant.” 
Some felt that lack of response to other medication may be a reason to join a 
trial:“Certain patients may like to participate because they do not have any other 
options.  Many tabs have already been experimented on him (patient).  It has not been 
beneficial to him then he does not have any option, then let us try new medicine… 
that may be the one of the reasons” 
“if there is no other medicines left for them, like suppose there is a such patient where  
there is no other medicine left for them, so maybe doctors want to try a new medicine, 
so it will be helping her or maybe he can take a risk whether this medicine can be 
helpful or harmful. so in that way it may be helpful.” 
Regarding monetary benefits one person felt it was morally incorrect to expect 
monetary benefits for participation in research, “..now we are staying here as a 
patient.  You are asking our help for the research study.  It is wrong to ask you to 
provide money for answering the questions which you asked…” Another stated, “If 
he is you know economically not strong, so for that for the monetary benefit he may 
try.  Otherwise for the money no one will try to take a new medicine, maybe due to 
some circumstances….” 
“Considering the risks in healthcare in new trials, healthcare cannot be compromised 
for monetary gains..” 
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Regarding trust in doctors and the organization doing trials, one person mentioned 
with regard to his experience with treatment of his relative, “I do not blame them 
(doctors).  They tried to enthuse confidence in me at that time, but I could not believe 
them at that time.  I did not have that much confidence at that time.  Even if I believed 
them, I wanted to have a third opinion….”.The same person also mentioned that the 
asking of consent raises fear, “No body asked for my consent while going for 
aripiprazole,… but while going for the clozapine therapy everybody is asking for my 
consent, why my consent, why they are not starting it, so they are asking for the 
consent itself raised a lot of fear, no doubt, fear in myself particularly regarding 
granulocytosis….(side effects)” 
Regarding the motives of doctors in conducting clinical trials, all the patients and 
more than three-quarters of the relatives felt that doctors do research trials with the 
sole aim of helping their patients.One participant stated, “They can find the medicine 
by doing a lot of tests as early as possible so that even the child in the mother’s womb 
can be prevented from this (illness).  So we can do something for this.  Thus, I cannot 
say that the doctors are doing for the fame or pride.  They are also doing the service 
that we are seeing by our own eyes….”However, additional motives such as 
conducting experiments and promoting their careers were also endorsed by the 
majority of patients and relatives. One person disagreed that doctors do trials to help 
their own patients. He felt that the benefits would take time and so immediate results 
would not be got.  
“… the research is not going to have any immediate result.  Only if it is beneficial, he 
will have to go a long distance to establish it.  Only after that the medicine can be 
generalized or approval to use the medicine in general can be given.” 





Agree (%) Disagree (%) 




(N = 8) 
Relatives 
(N = 10) 
Patients 
(N = 8) 
Relatives 
(N = 10) 
Patients 
(N = 8) 
Relatives 
(N =10) 
Need to test new drugs in 





benefits 4 (50) 3 (30) 2 (25) 5 (50) 2 (25) 2 (20) 
Monitory 
benefits 3 (37.5) 4 (40) 5 (62.5) 4 (40)  2 (20) 
Altruism 7 (87.5) 10 (100)   1 (12.5)  
Trust in 
doctors 8 (100) 10 (100)     
Duty to 




Experimenting 6 (75) 7 (70)  1 (10) 2 (25) 2 (20) 
Career 
promotion 4 (50) 6 (60) 4 (50) 3 (30)  1 (10) 
Mainly to help 


















4 (50) 3 (30) 3 (37.5) 5 (50) 1 (12.5) 2 (20) 
Do not address 
patients 
concerns 
4 (50) 3 (30)  5 (50) 4 (50) 2 (20) 
No privacy for 




randomization 6 (75) 7 (70) 1(12.5) 2 (20) 1 (12.5) 1 (10) 
Placebos not 





6 (75) 3 (30) 1 (12.5) 4 (40) 1 (12.5) 4 (40) 
Involving patients in 
designing trials not necessary 3 (37.5) 3 (30) 3 (37.5) 7 (70) 2 (25)  
Willingness to participate in 
placebo controlled trials 6 (75) 3 (30) 1 (12.5) 3 (30) 4 (40) 1 (12.5) 
Decision to participate is a 
family decision 5 (62.5) 9 (90) 1(12.5) 1 (10)   
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Participants also endorsed the difficulties patients faced in participation in trials with 
half the patients and relatives agreeing that lack of trust in the motives of the doctors 
and the organization doing a clinical trial would be a barrier to their participation, and 
three-quarters of the relatives agreeing that consent forms are difficult to understand  
by patients.  In addition, relatives added, “…because of the audio hallucination he is 
not able to understand the things directly. He requires more time to understand 
anything and if you disagree with him on any front he gets irritated…” 
“He even forgets whether he has taken the medicine or not. He cannot tell me 
certainly whether he has taken the medicine.  This is the state of his mind, so in that 
case he may not be able to understand these things; that is my perception.” 
More patients than relatives felt that clinical trials interfere with clinical care; do not 
fully address patients concerns about whether the drug is effective or safe; and 
participation results in a lack of confidentiality (Table 2). 
The methods used in trials in increase internal validity were endorsed by 75% of 
patients and 70% of relatives agreeing that randomisation was necessary. However, 
while 75% of patients agreed that using placebos in trials is not justified even if it is 
good way to do research, 75% agreed that if patients sign an informed consent form to 
participate, then randomisation, blinding and placebo comparisons are justified. The 
same proportions also expressed their willingness to enrol in placebo controlled trials. 
However, while 70% of relatives endorsed the need for randomisation, only a third 
agreed that placebos were not justified, or that informed consent justifies the methods 
used in RCTs.  
Some equated randomization as luck…“We are saying that this is their luck. You 
have already informed that it is just like the toss.  It is according to their luck.” 
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Others were pragmatic in their approach, “Generally I think patients will not be 
generally willing to take part in trial medicines because what everybody wants that 
new medicines should come and more beneficial medicines should come, but I should 
not be the first to try.  Let others be tried and I will take the benefit.  It is the general 
nature of general human…Everyday, we are coming across a new antibiotic, but no 
person wants that I should be the first man to try with the new medicine” 
“I may or may not take part that will depend upon the situation at that time… if 
patient is recovering well with the treatment given to him by the doctor, he may not 
agree for the trials, why waste time on the trials if the trials may be useful, may not be 
useful.  Rather it may leave behind some side effects also, so why to take 
risk…Theoretically many things are correct, but when things come to the practical 
life, most of the people fly away from the scene” 
“I want that only tested medicine should be used….  I do not want to take more 
risks..” 
The majority of relatives (90%) and patients (63%) felt participation in clinical trials 
is a family decision. However, one mother responded:“Patient alone can take the 
decision.  Patient’s cooperation is most important.  They won’t accept when we 
(relatives) tell them. Even though we are accompanying them they won’t accept….” 
While 75% of relatives disagreed with the notion that involving patients in designing 
trials was unnecessary, only a third of patients had clear opinions on this.  
Comprehension of the information regarding the hypothetical RCTs 
The ten questions assessing comprehension of the information provided for the 
hypothetical RCT were grouped as follows: 
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Four questions assessed the participants’ comprehension on equipoise, four other 
questions assessed their recall and knowledge of the specifics of the design, one 
question each assessed their comprehension on randomization and blinding, one 
question assessed their appreciation of risks.Table 2 details the proportion who 
provided correct responses to the questions.   
Table 2: Comprehension of information regarding the hypothetical RCT 
Themes 
Percentage (numbers) of 
patients who gave correct 
answers (N=7) 
Percentage (numbers) of 





1, 6, 10) 
43% (3) 40% (4) 
43% (3) 50%(5) 
43% (3) 50% (5) 












57% (4) 60% (6) 
Assessment of 







knowledge of design 
(Questions 3, 5, 8, 9) 
29% (2)  50% (5) 
29% (2) 60% (6) 
71% (5) 70 % (7) 
71 % (5) 40% (4) 
 
Overall, comprehension of the essential elements of the trial was poor for all 
participants in general, and for patients in particular.  
Comprehension of the information for the extension to the hypothetical RCT was 








of patients with correct 
responses (N=7) 
Percentage  (numbers) of 







71% (5) 38% (3) 




71% (5) 50% (4) 
3. Recall and 
knowledge of design. 
(Question 2, 4, 5) 
57% (4) 75% (6) 
43% (3) 75% (6) 
29% (2) 25% (2) 
 
Although most of the participants on enquiry, replied that they had understood the 
content in the information sheets, discussions revealed otherwise.  The concepts of 
randomization, blinding and use of placebo were not understood by many in spite of 
the detailed descriptions given in the information sheet. Many of them preferred 
listening to the interviewer explaining the content of the information sheet rather than 
reading the sheet themselves. Fewer patients could recall the specifics of the study as 
compared to the relatives. 
The sample size does not allow generalizing the results, but the general assessment of 
comprehension of patients of the concepts of equipoise, concept of randomization 
comprehension of risks involved was affected by their poorer ability to recall 
information discussed with them as compared to their relatives. 
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Willingness to participate in the hypothetical RCT and the extension to the 
hypothetical  RCT 
Table 4: Willingness to participate in the hypothetical RCT and its extension 
 Numbers (%) of patients  
(N = 8) 
Numbers (%) of relatives 
(N = 10) 
Likely to 
participate 






Hypothetical RCT  3 (37%) 5 (63%) 5 (50%) 5(50%) 
Extension RCT 4(57%) 3 (43%) 4(44%) 5(56%) 
 
Overall about fifty percent of the participants were willing to participate in either of 
the trials.More patients were willing to participate in the second RCT which required 
the continuation of usual drugs along with the trial medication without a wash-out 
period without medicines.  
The qualitative data for the discussions held towards exploring the reasons for 
participation were grouped under the following themes: 
Reasons for not participating 
Cognitive deficits were quoted as the reason by one patient, “Because I am forgetting 
everything… what I am reading… how can I remember the name of the drug or the 
chemical…I will not be able to write and give the side effects…”  
Side effects: “I do not feel like going into any new medicine trial.  The medicines, 
which are already proved right and is generalized that had so much adverse effect on 
me that I dare not to go on any medicine that is not yet proved.”   
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“I am already known of the fact that my body is so much sensitive to the psychotic 
medicine, how can I go with the trial?  It makes sense? how can I go with the trial?”  
“One thing is sure any psychotic medicine does not have good side effect.  It is bound 
to trouble the patient and during my experience in this field in the last two years with 
my son, I have come to learn this that no psychotic medicine has good side effect”. 
“When I do not have any option, we have to treat the patient to get him cured.  Along 
with the recovery, he also happens to get some (side) effect.  Then somewhere we 
have to make the compromise and let this compromise be made with the known 
medicines…known and tested,… that is my personal opinion.”   
“(relatives) would fear that her other problems might increase or maybe that medicine 
may not go hand in hand with whatever medicines she is taking…Or maybe (she may 
have) some type of side effects”   
Lengthening of the hospital stay:  
“Once my patient takes part in this study, the usual medicines with be withdrawn 
temporarily and he will be put on new medicines.  This is likely to lengthen the 
treatment period here.  That I cannot afford.  This is the first reason to refuse the 
participation”  
“even for the four weeks suppose if they have got an option that just for the trial we 
have to stay for four weeks then maybe most of the people will say no unless they live 





The drug tested being inappropriate for the primary disease: 
“he is already suffering from schizophrenia of perhaps the high degree and this 
medicine is not meant for schizophrenic symptoms.  This is only meant for stress, so 
this medicine may not be useful for his original disease.”   
“if we consider the present condition of  (the patient) and then judge this medicine 
then maybe it does not suite her requirement” 
Stopping of usual medication: 
“What has made me to make the decision that at this stage( he) will not be going for 
any clinical trial simply because it will remove all the medications that are being 
given to him.  This will bound to create problems…Stopping altogether the current 
medicine and putting the patient on the new medicine.  That would have jeopardized 
the whole current treatment process.…”  
“…to do this trial, the other medicine maybe whatever she is taking, would be 
reduced.  Neither doctors maybe agree and maybe we will also not agree”.  
“Doctors have told us to continue medication. Now you are saying medication will be 
stopped… now I am scared that the similar illness will come back…” 
“if my usual medicines is not given my problem may not reduce.” 
If the current medication is stopped I am scared about what will happen…”   
“He cannot miss this medicine..which is brain medicine for a single time… it must be 




Treating doctors would not recommend stopping medication 
“What is the purpose of the trial, whether to make her better or to make this trial a 
successful one? Because seeing her condition I don't think the doctor will say yes (to 
stopping medication)…”   
“I know such a situation will not arise because what is technically possible that only 
will be advised by the doctor.”    
“Patient is eating the medication her doctor has given…in between if we go and join 
this trial… how will we answer them….?” 
Severity of the current illness 
“Because my patient at this stage is in a critical condition,  I already lost about two 
years in treatment and now I do not want anymore experiment regarding the 
medicines.  What I want only tested medicines should be used in this case..” 
“I myself am in such a worsened condition… suppose it gets even worse after I take 
the ordinary  tablets…”   
“Maybe (if) her condition was not so severe, and if the doctor would have 
recommended, we may have gone for that (the trial)..” 
Other treatment options being available 
“I could have agreed to this trial test had there been no other options left for me, but 
as on date I think they are certainly other options available, so at this juncture I am not 
prepared to let my boy participate in the trial.”   
“At present if we are trying clozapine on her. Like, suppose after one year, we find 
that is also not working… Then, we will say yes because we don't have any other 
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options.(but)now when she is already being tried on clozapine and if you say okay for 
our research purpose let us try this medicine, I will say sorry..”   
“Even if the doctor recommends I won’t take part..now I am better .. now why should 
I try other medicines?” 
Blood tests: 
“Ddifferent types of tests are to be carried out during entire procedure.  That is certain 
to put extra burden on the patient Psychological load on him ….”   
“Sschizophrenia is such a disease that I cannot predict whether if he agrees today, he 
may not agree tomorrow.  Once he sees that EEGs and ECGs are being conducted on 
him, he may think that trial itself is false and actually being treated differently for 
earlier disease.  These things may come in his mind”   
However, some opined that blood tests were not a problem: “I have given blood 
earlier and I know that that is not a big issue, so it does not matter.”  
“Not much concern..because even for the normal treatment blood tests are done.”   
“ blood tests are very simple… no problem to health…these are the usual tests done .. 
so no problem…” 
“I am afraid of needles… even if I had malaria and was sick I would not give blood 
tests… but I will agree to it for her(patient) because I want her to be well…”  
Family disagreeing 
“My wife is not going to agree. Mothers are more possessive of their children..more 
concerned.  I think in general.  Father may take some risks, but mothers will not.  It 
may or may not have a detrimental effect, but she will never agree. She may not think 
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in broader terms that I do have the courage at times to think over… I think this 
scenario exits in every Indian family”.   
“But as I am under the parents, I will listen to what they say. I don't think they are 
interested…”  
“ (if )you have signed the consent slip maybe even with their(family members’) 
consent, but afterwards the family members say I was telling not to go for that. Who 
will answer them if something goes wrong?  Then, how you will be able to face them?  
They will accuse you.  Nobody would like to get accused…” 
“I can say only after I ask my husband….”   
“Once we join the trial you want us to come back… but will her husband allow her to 
be brought… I don’t know I can decide only after asking her husband.. I cannot do 
anything without asking him…”    
“If I take a decision alone and something happens then my husband will ask me why I 
did not enquire of him..” 
Inconveniences 
“I am from a faraway place… there are children at home… we cannot come for these 
trials…”  
“I cannot take part in this research.  Because I am having children, if I participate 
nobody is there to stay with me.  I have to stay alone.  My health condition is not 
good. Nobody is there. Today my brother is here.  He cannot stay because he has to 
go for work..” 
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“We cannot stay here for four weeks… even getting meals here is expensive… my 
husband staying at home also is eating from a hotel…”  
Personal ‘weakness’ 
“Situation is very paradoxical actually. Only trial that is carried out on animals, 
mouse, cats, is not enough for the medicine to be tried upon the human.Still 
everybody does not have that much courage to participate. Maybe, I am weak 
there…You will find many more persons like me.  You may find many brave persons 
who would like to encourage in the tests, but the number is perhaps less in India and 
perhaps this is the reason the Indian scientists have not been able to bring forth new 
medicines at the rate expected of him”   
Lack of education 
“Because knowledge is less; there are less educated people.  There are more illiterate 
people. ‘why should we come forward first?’ that sort of attitude’ also spreads to 
educated people…”    
“the education level and era comes in.  The people of this era..who have some 
scientific background or who know that some researches are  necessary may say yes, 
but it could be very difficult to convince the fathers and grandparents and all that”  
“because people who know that these are the research, this is the science and all that 







“ i can only take the medication I choose…”   
Some thought of it as ‘luck’ and ‘athishti’, “if you don’t know and I don’t know (what 
medicine will be given)… then it is our luck…I don’t have a problem with that…”   
“I wont know what medicine I will be taking… that will be difficult for my health…” 
“my doctor knows my condition, so if my doctor does no thave a choice in ( what 
medicine I will get) my health will become worse” 
“If doctors are not sure of what medication will be given them I am scared” 
Reasons for participating 
Altruism:  
One patient opined, “It is for a good cause that's it. I am in a situation to be 
participating in this to get a good solution to a problem, but whereas other people may 
not begin, but they might be requiring it, so in that case I can help them out..helping 
people that's the sole motive for me, at least for me ….” 
“Participating will provide a new medicine for other people. This can help other 
people” 
“I am interested that’s why I have (consented)… if some part of the distress (for a 
psychiatric patient) is abolished then what s the harm in that..he will be relieved…” 
“It is my nature… I like new things to come… if it is successful it will give a new 





“Personally do, yeah because if I get to suffer that sort of a disease in future, maybe I 
might be getting those medicines too to sort out this problem.  Who knows?”   
“Food also needs to be given… you are providing for conveyance, lodging… food 
also has to be provided” 
“Some monetary compensation must be there from the research side..he is 
volunteering to give so many tests…he must get a medal at least…” 
Trust in doctors 
“Doctors won't stop(medication) for nothing.  There will be a reason behind it and 
that would not let me down that much.  That belief in doctors helped me arrived at the 
conclusion. I firmly believe that doctors will help me to come out of a problem if it 
arrives... ”   
“Everything can be done on the patient if the doctors suggest it is good to go for it..” 
“I may not have a problem. I see earlier the research and all are very authentic and if 
the doctor recommends”   
“ I am not worried (about dummy medicine)…. You (doctor) know about it…the side 
effects of the dummy tablet, or the side effects of GVV tablet is known by the 
doctor… I don’t know. And doctor (should) what should be taken.” 
“Doctor’s choice is perfect…”  
“ I will ask you to do whatever you wish…we don’t know what medication should be 
given to whom… but you (doctors) do, and you are taking care of crores of people…”  
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“ if anything to be scared of was happening in this hospital would so many people be 
coming here?….”  
“Anyway doctors will take care… whatever you give is like God has given….”   
“If anything happens after giving the dummy medicines , the doctors only will take 
care.. so I am not scared… you (doctors) can do everything.. we can do nothing…” 
“ because you are asking I will agree… I feel that you will not ask me to do 
something that will harm my daughter. So with that trust I am agreeing to participate. 
I believe you will want to do only what is best for me.”  
“Whatever you do you are doing as doctors.. so if it is good or bad we will accept 
it…whatever the doctor gives it will be for the patients good and so we will accept 
it…”  
Recommendation of the treating doctor 
“If the treating doctor recommends we will participate madam… nothing else needs to 
be asked..we will join…”  
Monetary benefits 
A patient opined:“You said “your stay will be free of cost for the four weeks you stay 
here” that helped me to arrival of this decision because we are not that well off to pay 
for stay for a long period of time.  It was a good incentive that helped me to arrival of 
this decision…”   





Choice between the first and second study 
Many of the patients favoured the second study because the usual medication would 
be continued:“Because required medicine will go on regularly and the new medicine 
also be tested, but in the former one the medicine will be completely stopped and the 
level of the medicine in the brain will get down, so all the hard work from two to 
three months will go in vain”.   
“surely (the trial)in which the usual drugs are continued.  It would be always liked if 
the usual drugs are continued..” 
Opinions on patients participating in designing trial 
“These studies are done on patients… so they have to help design trials…”. 
“One or two people..who you think are credible.. maybe 30 percent of the people 
participating.. they may give economical, theoretical points or research related points 
…”  
Other factors influencing the choice: 
The fact that the medication came from outside India, “the persons willing to go in 
trial I think will be 1/10 persons...Because it is risky.  So many side effects can occur.  
We do not know anything.  This is coming from outside India. Why they are 
experimenting in our country?  Why are they not experimenting in their own country? 
You test on your own people and then it will be okay, then send to my country”.  
“Medicines are being supplied from Switzerland…. Suppose due to some reason, the 
supply of medication gets stopped. Then what would happen to the patient?” 
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Another relative felt it was good if the drug was imported, “it doesn't matter, the 
medicine from Switzerland is good.  Indians would like imported, so if it is from 
Switzerland, it is good”   
 Other issues 
Some patients had difficulty expressing the reason for a choice:“..no reason.. I cannot 
express…” 
Some had never heard of research, “ I have never even gone to a hospital before.. I 
have delivered five children but still have never been to a hospital… I have not heard 
of such things as research and testing medication…”  
“I have not heard of such things as research and trials…” 
“I don’t know…I won’t join.. I don’t know why.. I am scared if some problems will 
arise…I don’t know how to say…” 
“I cannot understand why you are asking questions like this….” 
“It is difficult for me to answer these questions you are asking…” 
One relative mentioned, “I don’t mind participating In a real trial..but I must get a 
confident reply on an authenticated document undertaking that the trial is conducted 
and we will give you the patient the same.. back.. “ 
Opinions regarding dummy medicine 
“What dummy medicine?... “dummy”.. that is not medicine… that is called poison… 
it gives harm to the patient.. you have written “dummy”.. the word gives me more 
pain…”    
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“Madam whatever medicine you give her she must become normal. if she goes back 
to her previous state it is scary isn’t it …its three months since we came here and now 
she is better.. if you now give her dummy medicine and then something happens.. 
Then?” 
“I have no concerns about he dummy tablets.  It is not in anybody’s hands..” 
“All these tablets are related to the brain..if something.. even a small chemical 
reaction happens in the brain…I am scared of what will happen…” 
“Do not give dummy medicine.  What is in use of giving the dummy medicine?  It 
won’t work in the patient’s body.  There is no chance of curing.  Then what is the 
use? …” . 
Observations noted during the conduct of the interviews. 
Field noted were maintained as a part of recording the context and other non-verbal 
behaviour which was noted during the process of the interviews. In one instance, the 
patient who was during the informal rapport building session judged to be competent, 
became disturbed and started behaving inappropriately during the interview. This 
happened after administering the attitude questionnaire and due to this the interview 
had to be discontinued.  
In another instance, after one session of the interview, the patient was unable to judge 
the study as an imaginary study and expressed a strong desire to the relatives that he 
wanted to join the trial. The relatives were upset due to the change in behaviour of the 




Objective assessment of competence: the MacCAT-CR interview results 
We completed in total 5 MacCAT-CR interviews; twowere with patients and relatives 
for the first as well as the extension to the hypothetical trial. One of the relatives did 
not take part in the interview for the extension RCT because of impending discharge 
from the ward. The other relative of the patient did not give consent to interview the 
patient as he felt the patient was not competent to undergo such “complex” interview 
process. This patient was clinically also found to be incompetent later during the 
process. The 3rd patient could not undergo the MacCAT-CR interview as the patient 
became physically ill and had to be shifted to the medical ward at the time of the 
scheduled interview, but the relative could participate.  






































1 17(65%) 4(15%) 4(66%) 0 (0%) 4(50%) 2(25%) 2(100%) 2(100%) 
3 24(92%) 21(80%) 6(100%) 5(83%) 7(87%) 3(37.5%) 2(100%) 2(100%) 
6 5(19%) 25(96%) 2(33%) 5(83%) 2(25%) 2(25%) 2(100%) 2(100%) 
8 23(88%) - 6(100%) - 6(75%) - 2(100%) - 







1 15(57%) 1(4%) 2(33%) 0(0%) 4(50%) 0(0%) 2(100%) 2(100%) 
3 26(100%) 20(77%) 6(100%) 5(83%) 6(75%) 3(37.5%) 2(100%) 2(100%) 
6 - 20(77%) - 5(83%) - 2(25%) - 2(100%) 
8 24(92%) - 6(100%) - 4(50%) - 2(100%) - 
13 8(30%) - 3(50%) - 1(12.5
%) 
- 1(50%) - 
 




Since the cut-off scores have not been validated in the Indian population, the scores 
were evaluated in four ways: 
1. The proportion scoring 50% or more on the four domains of understanding, 
appreciation, reasoning and expressed choice to be subsequently judged as 
competent: 
The basic expression of choice is unequivocal and clear in both patients and their 
relatives; whatever be their choice.Understanding and appreciation of the concepts 
of the randomized controlled trial of both the placebo and extended arm was 
found to be overall adequate.The reasoning domains especially with patients were 
found to be much below the level of acceptable 50%. Both consequential and 
comparative reasoning was found to be inadequate. 
2. The performance of participants’ competence was evaluated using stringent 
standards (adequate on all domains): Two relatives (nos 3, 8) was competent using 
this standard for both trial scenarios, while another relative (no 1) was less 
competent to consent for the extension RCT than the first RCT. None of the 
patients met this standard. 
3. Using intermediate standards (adequate on three domains: Understanding 
information, appreciation of the significance of the information, reasoning with 
the information) No patient was judged competent with this intermediate standard. 
4. Using the least stringent criteria (Understanding information). One patient (No 1) 
and one relative (no 6) were found not competent even using this least stringent 
criterion. 
Clinical assessment of competence had found all these participants to have 







Summary of the results 
Attitudes towards randomized controlled trials: 
The general attitude towards trials was positive in the patients and their relatives and 
all the participants acknowledged that it is necessary to test new medication before 
they are made available for general use.  
Trust in doctors was a very notable recurring theme in all discussions. All of them 
agreed that trust in doctors and the organisations where research is done was very 
important for participation in trials. 
Willingness to participate in a hypothetical randomized double blinded placebo 
controlled trial  
Overall the results showed that only about 50% of the participants were willing to 
participate in the hypothetical trial. This shows a similar trend as compared to the 
rates discussed in literature including a study conducted in a tertiary care setting in 
India [72].Possibility of side effects, both known and unknown, and the possibility of 
worsening of the disease on stopping regular medications are important issues that 
play a role in the acceptability of trials especially in the psychiatric population. 
Placebo controlled trials which require a drug washout period are hence perceived as 
a hazard by many participants. During the regular inpatient treatment in hospital much 
importance is given to ensuring compliance in people with psychiatric illness. 
Researchers approaching patients for trials which recommend a washout period may 
be perceived as going against the principles of beneficence upheld by the treating 
team. This could create confusion in the minds of people with regard to the motives of 
the research.  Hence much care and thought has to be given with regard to discerning 
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between psychiatric conditions in which placebo controlled trials would be not just 
ethical but also acceptable to the participants in terms of safety and risks, and those 
conditions in which risks expected are unacceptable. This also highlights the 
importance of ethical issues in clinical care being not considered separate from those 
in research and highlights the role of “therapeutic misconception” influencing patient 
perceptions of interventions offered in clinical trials [41, 50]. 
Perceived barriers and facilitators affecting participation in randomized controlled 
trials 
The meta-analysis by Shah and colleagues [69] includes expectation of benefits 
related to health, altruism, faith in doctors, expectation of additional income, thorough 
information about trials and methods for inspiring participants as factors favouring 
participation in trials. Distrust in organizations conducting trials, concerns about 
usefulness and risks of trials, psychological issues, trial burden, loss of 
confidentiality, dependency related factors, and problems related to the language of 
communication were quoted as the barriers to participating in trials. 
Similar results were shown in our study with regard to trust in the doctor and altruism 
as factors improving participation. Other recurrent themes discussed as reasons for not 
participating in the hypothetical RCT were the severity of the illness, the fact that 
other already proven options were available, and that the decision required 
consultation with other members of the family. 
Issues related to informed consent in patients suffering from psychiatric illness 
Comprehension of the participants 
Acceptability of trials could be improved if informed consent is considered as a 
process rather than an event marked by the signing of a form. Including verbal 
interactive discussions as an adjuvant to written information would aid in encouraging 
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clarification of doubts, dispelling unfounded fears and improving 
participation.Problems related to recall of specifics regarding the study were found to 
be more among the patients as compared to relatives. This may be due to the residual 
deficits associated with the disease but further research is required to explore the 
presence of other factors contributing to the same. 
Even among relatives about half the participants were unable to understand the 
concepts involving randomization, equipoise and blinding. 
Among patients, the understanding of equipoise was better following the discussion in 
the extension RCT as evident by the increased percentage of patients who answered 
correctly. This could point to the advantage of repeated explanations.Assessment of 
the comprehension of risks also showed better scores in the extension RCT as 
compared to the first hypothetical RCT. 
Assessment of Competence of participants 
In this study, the clinical assessment of competence of the participants was done first 
during the rapport building time prior to the interviews. Patients who were initially 
assessed to be competent by this method were later on found to be not competent 
during the discussions necessitating a discontinuation of the interview. Competence is 
a complex construct which encompasses multiple dimensions requiring formal 
assessment. Formal assessment of competence should be an adjuvant to the mental 
status examination in declaring a patient to be competent or non-competent. Issues 
regarding whether the process of discussion regarding the trial are anxiety provoking 
and stressful need to be further explored since competence is assessed in the context 
of the decision-making process.   
The assessment of competence in this study was done clinically on the basis of the 
degree of comprehension of the patients and their relatives of complex constructs of 
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research which they had never heard of before in a tertiary care setting wherein they 
had come to seek treatment. Whether this was an important factor because of which 
many patients and relatives were judged incompetent needs to be seen in a larger 
representative sample. More so because the objective assessment of competence using 
the MacCAT-CR in a subset found most to bedeficient in consequential and 
comparative reasoning processes. The fact that almost all could express their choice 
in-spite of this deficit might point towards the fact that a lot of people including 
patients and relatives take decisions based on trust rather than logical reasoning 
process.  
The findings from this study point to the need for a more comprehensive method of 
assessing competence which would add on to the mental status examination in 
declaring a participant as competent or not. Assessment of the relatives for 
competence in understanding the issues involved in RCTs may also be required in 
view of the fact that in this study many of the relatives also were found to be not 
competent at the end of the discussions.   
The justification of the methods used for the study. 
There is a need for more information on the subjective perceptions and opinions of 
people with psychiatric illness about randomized controlled trials. The attitudes of the 
patients and relatives towards these trials need to be explored to identify common 
issues which can be addressed to improve participation in future. Cultural differences 
in attitudes are also important.  
Qualitative research methods are known to enable a rich descriptive understanding 
into the complex aspects of subjective experiences. The “Prospective preference 
assessment” method provided a framework within which the willingness to participate 
in trials could be assessed and qualitative methods of face to face interviews enabled 
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exploration into the reasons regarding the choice to participate or decline. These were 
combined with quantitative assessments of the willingness to participate and the 
competence of participants to further address issues related to informed consent and 
assessment of competence. 
The transferability of the results 
Patients were recruited from a tertiary care inpatient facility. Since such patients are 
likely to be the ones approached to participate in research and since they are also 
more likely to have impaired decisional ability than outpatients, the result of this 
study would have value in applicability to other similar settings in India. The opinions 
of their relatives are also likely to reflect those of relatives in other settings. The 
concerns regarding people with psychiatric illness are very different from those of 
patients with other physical illness and the study has attempted to identify these 
issues. The perspectives and opinions of relatives of patients with psychiatric illness 
are also different from the general population and this study tries to highlight the 
complex nature of the issues faced by them in consenting to allow their relatives to 
participate in randomized controlled trials.   
Limitations of the study 
The lower than expected recruitment into the study resulted in suboptimal numbers of 
participants providing data from this study to adequately inform attempts to improve 
the understanding  of factors important to patients and relatives regarding trial 
participation. Rapport was a very important factor deciding the quality of the data. In 
cases where rapport was difficult to establish with the participants the quality of the 
interview was compromised. 
A hypothetical RCT was used to find out the attitudes and willingness to participate 
and this may not exactly reflect the opinions of those who are actually called for real 
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trials. However, the responses of participants are indicative of a cross-section of 
opinion of potential trial participants.  
Due to time constraints the translations of the Tamil version of the questionnaires and 
interview guides could not be back translated into English. However in most cases 
when Tamil was the medium of communication, the participants requested the 
investigator to explain to them the content in the questionnaire and consent forms and 
did not prefer to read it on their own.  
The attitude questionnaire was not a validated tool, but since it was not designed to 
give a score, rather was used as an aid in guiding discussions on required topics. 
The voice recordings for one participant (serial no.18) were of poor quality and hence 
could not be transcribed. 
Data from a few Tamil and English files could not be transcribed completely in time 
and hence only relevant parts were transcribed into English. 
This study did not aim to make formal correlations between psychiatric symptoms, 
cognitive impairment, and competence to provide consent. Hence more appropriate 
tools for formal assessments of psychiatric symptoms, and cognitive deficits were not 
used to make such evaluations. 
Strengths of the study 
This study was designed according to the COREQ standards for qualitative studies 
and also provided quantitative data and included detailed transcripts of audio-recorded 
interviews.  
A number of steps were taken to minimise biases. Selection bias wasaddressed by 
consecutively assessing all admitted patients into the study who fulfil the eligibility 
criteria and consented. Representativeness was addressed by ensuring that at least half 
the patients have a psychotic condition and the remainder will comprise non-
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psychotic conditions; all participants will have a CGI score of at least moderately ill. 
Bias due to the nature of the acute illness reflecting in lack of capacity to consent was 
dealt with by repeating the consent assessment after an additional week in those felt 
on clinical assessment to lack the capacity to consent. 
The structured MacCAT-CR manual and scoring were kept away from the primary 
investigator, who assessed competence using clinical assessment that is used routinely 
in clinical care. While, the domains of the MacCAT-CR are known to to the 
investigator, the relative importance given to each domain while scoring, and the 
structured manner in which the MacCAT-CR is used differed from a clinical 
assessment of competence.  
All the instruments used for this study were assessed for cultural and linguistic 
appropriateness and pilot tested with records made of any alterations.  
Field notes were kept during interviews to record contextual data.  
Recording the interviews and evaluation by an independent professional helped 
minimize ascertainment bias and bias due to erroneous interpretation and recall, and 







This cross-sectional study using quantitative and qualitative methods and using the 
Prospective Preference method to ascertain the views of psychiatric patients and their 
relatives towards participation in clinical trials revealed that while patients and 
participants consider it necessary to conduct RCTs for scientific purposes and 
consider participation in these trials as an altruistic imperative, and the methods of 
RCTs that increase internal validity appropriate; their willingness to participate in 
such trials are likely to be increased by trust in their doctors and the organisations 
they represent, as well as by personal health and financial benefits, and the opinions 
of family members;  and reduced by a variety of factors that include potential risks 
and burdens associated with trial participation. Comprehension of information 
required to provide valid consent is likely to be sub-optimal, but could be enhanced 
by conversation and repeated explanations, supplementing written information. Even 
then, roughly 50% approached to participate in such trials are likely to refuse 
participation. The prospective preference method has value in informing the design of 
future trials. Finally, formal assessments of the capacity to consent is routinely 
recommended in trials involving psychiatric patients, even if clinical assessments 
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Assessment of attitudes towards participation, willingness to participate, and 
competence to participate in Randomized Controlled Trials 
Title of the study : 
Dr. Donae George; Dr. Saumil Dholakia; and Dr. Prathap Tharyan; Christian Medical 
College, Vellore. 
Name of the investigators and institution: 
My name is Donae George and I am a doctor working in this hospital. I am 
approaching you to help me with my research study that I am doing as part of the 
training for my MD degree in Psychiatry. I am inviting you to participate in this 
research study and wish to provide you with information about this study. I hope that 
you will give me your permission to participate in this study after you have 
understood what this study is about and what you will be expected of you, if you 
decide to take part in this study. 
Invitation to take part in a research study 
This information sheet provides details of the proposed study and I request you to go 
through this information and allow me to answer any questions you may have about 
this study, before you make your decision.  Your decision on whether you will or will 
not participate is entirely up to you. Taking part in this study does not form any part 
of the treatment being provided at this hospital. Whether you decide to take part or not 
take part in this study will not affect the treatment you will receive at this hospital. 
The doctors who are treating you are aware of the details of this study and have 
permitted me to invite you to consider taking part in this study. This study has been 
approved by the Christian Medical College and Hospital. Dr. Saumil Dholakia, one of 
the consultants working at this hospital, is helping me with this study and Dr. Prathap 
Tharyan, a Professor of Psychiatry at this hospital is supervising my work. 
What is the purpose of this study? 
In this study we aim to interview 30 people with psychiatric problems admitted to this 
hospital and one relative of each of these patients. The purpose of this study is to 
understand the opinions of people with psychiatric problems and their families about 






What kind of research is used to study new medicines? 
Any new medicine that is being considered to be approved by the government to treat 
people with any medical or psychiatric problem needs to be first tested in research 
studies on people with that condition. This research first involves studying the effects 
of this medicine in the laboratory and later on a few people to find out what the dose 
to be used is, and whether it is safe to take this new medicine.  Once this is done, the 
new medicine is then again tested in many more people by comparing the effects of 
this medicine in people with the medical or psychiatric problem who take them and in 
people with the same problem who are not given this medicine. This is the only way 
that we can be sure that whatever any improvement or problems reported by people 
on the new medicine is actually caused by the medicine and did not happen by 
accident, or by chance; or due to any other reason.  
One of the other reasons why the new medicine may appear to be better or not as 
good is because the doctor selected the people into the study in a particular way; those 
selected people who got the new medicine were either more or less sick than people 
who did not get the medicine at the start of the study. It is important to make sure that 
the effects of the medicine are clearly due to medicine itself. The method used to do 
this is to choose each person by a coded system similar to a lottery, or like tossing a 
coin.  This method will help to make sure that everybody in the research study has an 
equal chance of getting the new medicine or not getting the new medicine. The doctor 
does not directly decide what treatment the patient gets and the patient cannot chose 
whether he or she gets the new medicine or does not get the new medicine.  
However, the doctors and people who do not get the new medicine might come to 
know as these people would see other people who got the new medicine either feel 
better or develop side effects To prevent this from happening, those who are not 
selected to get the new medicine will get an identical looking medicine that does not 
contain the new medicine, but contains a powder that has no bad or good effects (a 
placebo or a dummy medicine). Because it looks and tastes identical to the new 
medicine, the patients and the doctors treating them will not know who is taking the 
real medicine and who is taking the dummy medicine. If we do not use these methods 
in research studies before we prescribe them in larger numbers, we cannot be sure that 
new medicines really work.  Most of the medicines all of us take to treat different 
problems have been tested in similar research studies where other people have agreed 
to take part even though they did not know exactly what medicine would be given to 
them. All of us who have taken treatments with medicines have benefitted from the 
actions of those people who took part in such research studies.  
Because these research studies (called Randomized Controlled Trials or RCTs) are 
different from what happens when people normally go to doctors for treatment, it is 
important that people understand the differences. It is also important that they give 
their permission to take part in such research studies voluntarily and after knowing the 
details of the study. The difficulty is that since people are so different, not everyone 
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may want to take part in these studies and not everyone may be able to understand the 
details of such studies.  Some people may also be more willing to take part in such 
studies if the details were explained to them to their satisfaction and if the researchers 
understood the difficulties and concerns of patients who participate in research, and if 
the RCTs were designed in ways that helped patients who take part.  
The research study that I am doing does not involve actually giving you any 
medicines. In my research, I wish to find out your opinions about such research 
studies so that this information will help us understand how to do them better in the 
future. 
What will you have to do if you agree to participate? 
 
There are three parts of the study. The first and second part will be conducted by me 
and the third part by my colleague Dr. Saumil dholakia.  







                               Invitation to take part in an imaginary study 
 
  Reading and understanding the information sheet for the 
imaginary study 
 
  Clarification and check to see the understanding of the study 
  
 
 Decision by you and your relative to agree/decline to take part 
in the study 
 
     
 Agree decline 
                   
                                 Questions about what made you take this decision                                                                            
                                                                                       
 
Invitation to take part in an extension  
Of this study. Understanding the information regarding  
Extension of this study. 
 
Decision to agree/decline to take 
Part in the extension of the study 
 




If you agree to take part in this study, I will first request you to sign a form that states 
that you agreed to take part in this study out of your own will after understanding all 
the details of this study, and were not forced to take part. This does not mean that you 
cannot withdraw your permission at any time after signing the form as it is only meant 




I will then interview you in a private place and this interview may last for roughly one 
hour, though it may take less time or more time, depending on how easy or difficult it 
is for you to understand the questions you are asked. If you feel tired at any point, I 
will stop the interview and we can do the remaining part of the interview at a later 
time.  I will interview patients and relatives separately unless you specifically wish for 
your relative to be present with you.  
In order to make sure that I do not forget what you said during the interview or that I 
do not make mistakes about what you said during the interview, I request that you 
permit me to record the interview using a voice recorder. This will permit Dr Prathap 
Tharyan, my supervisor, to listen to the interview and check any mistakes in my 
impressions about the interview. By listening to the recordings of the interviews of all 
the people who take part in the study, we will be able to compare opinions, and 
identify common concerns or view-points. This will help us improve our 
understanding and will help us make better conclusions about this research. You will 
not be personally identified in this recording and I will give you a code number so that 
nobody actually knows whose voice was recorded apart from me. 
I will ask you (if you are a patient admitted to this hospital) details about yourself and 
your psychiatric condition and treatment. If you are the relative of a patient, I will also 
ask you details about yourself and your relationship to the patient. I will write down 
this information. 
I will then give you to read, and also read out, a questionnaire that asks you about 
your opinions about taking part in research studies involving the testing of new 
medicines. These questions discuss the methods that were described in the first part of 
this information sheet. This is not an examination or a test of your memory or 
understanding but an attempt to find out what you feel about these kinds of studies 
and their methods.  
I will then give you an information sheet similar to this one and will read it with you. 
This information sheet is an invitation to participate in an  IMAGINARY study where 
the people who participate will be given either a new medicine for their problem or a 
dummy medicine. The information sheet will describe the details of the new medicine 
as well as the details of what people who take part in the research will have to do. 
This information sheet is very similar to what people would actually receive when 
they are asked to participate in research on new medicines. However, this invitation is 
NOT for a real trial that you are expected to participate in, or approve as the relative 
of a patient, but only an exercise to understand what you feel about being invited to 
take part in such a trial. It will help my study if you can imagine that you were 
actually being invited to participate in a real study of a new drug.  
After I have given you an opportunity for you to ask questions about this imaginary 
study, I will then check to see if you have understood what the study is about and will 
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ask you some questions about the methods of this imaginary study and what will be 
expected of you.  
I will then ask you (as a patient) and your relative to decide whether you will agree to 
participate in the imaginary study and are willing to sign the consent form, though 
you will NOT be asked to actually sign the form.  
If you (as a patient) decide not to take part in this imaginary research study on the 
new medicine, I will ask you some questions about why you decided not to take part. 
You are free to state whatever reasons you wish to give as this will help us understand 
what part of the research made you decide not to take part. If you are the relative of a 
patient, and decide that the patient should not take part in this imaginary study, I will 
ask you for your reasons and encourage you to help us understand your reasons for 
this decision.  
If you (as a patient) decide to participate in the imaginary trial, I will then ask you 
some questions about what made you decide to participate. If you are the relative of a 
patient, and decide that you feel that that the patient should take part in this imaginary 
study, I will ask you for your reasons and encourage you to help us understand your 
reasons for this decision. 
If you (as a patient) decide to participate in the imaginary trial, I will then invite you 
to participate in an additional part of the same trial that requires you give some blood 
on different occasions and to take part in some special tests. I will again test your 
understanding of the information given to you about this extension study. You will be 
asked for permission to take part in these additional parts of the study and your 
decision and the reasons for your decision will be noted. If you are a relative of the 
patient, you will also be given information about the additional parts of the study, you 
understanding assessed, and your opinion on whether your relative should or should 
not take part in these extensions will be noted along with your reasons. With this my 
interview will end.  
For the next part of my study, I request your permission for my senior, Dr Sumail 
Dholakia who is a consultant psychiatrist in this hospital, to again interview you 
regarding your understanding of this research study as well as the imaginary research 
study using a different set of questions. This interview will take place within 24-48 
hours of my interview and should last about half an hour. He will also request you to 
permit him to record the interview with him using a voice recorder. The questions he 
will ask will help us understand how well you understood the research study and 
whether you made your decision with all the required information. This will also help 
us to decide whether we need to use these questions routinely when we invite people 




If you agree to participate in my research study, what will be your 
responsibilities? 
If you agree to take part, all you will be expected to do is take part in the interviews 
and answer the questions to the best of your ability. No other responsibilities will be 
expected of you. 
Will information from this study be kept confidential? 
Yes. Information collected for this study and all your opinions and your answers to 
the questions will be kept confidential. We will make sure that you will not be 
identified by name or in any manner that will reveal your identity in any way. Only 
the people named in this information sheet as the investigators will know who you are 
and the voice recordings of your interviews will not have your name or identifying 
details and will only have a code number that will be known only to me.   
What are the benefits of taking part in this study? 
Since we are not changing or adding to the treatment given in this hospital, taking part 
in this research study will not directly benefit you. We will also not be providing you 
with any financial or other compensation for your participation. However, taking part 
in this study will help you to learn more about how research is done for new 
medicines. Your taking part in this study may help other patients in the future, as this 
study will help us to understand how to make research more helpful for the patients 
who actually take part in research involving new medicines.  
What are the possible risks or harms that can happen due to taking part in this 
study? 
We do not believe that taking part in this study can cause any harm to you. If any of 
the questions are distressing you are free not to answer them. If the interview is 
distressing, or tiring, please tell me and I shall make sure we stop the interview and 
hope we can complete it later, if you agree.  
Is it possible to withdraw from the study, after I agree to take part? 
You do not have to agree to take part in this study. Even if you agree to take part, you 
are free to take back your consent and discontinue your participation at any time. We 
will ask you for your reasons for not participating or for deciding to stop talking part 
after agreeing to do so, but you do not have to give us any reasons, if you do not wish 
to do so.  
Your refusal to participate now or at any time will not upset us or make us displeased 
with you or change the attitudes of the hospital staff towards you or affect your 




Who is paying us for this research? 
None of us are getting any money personally for doing this research. The costs of 
preparing the paper forms for the interviews and for translating and writing the 
recorded conversations and for analysis of the results are being paid from money 
given for this purpose by the Christian Medical College, Vellore.  
Can I find out what were the results of your research study? 
We hope to publish the results of this study in a medical journal that will present the 
overall results but will not give the results for any individual person who took part in 
this study. Any result that is from any person will not be identifiable from the 
publication report.  
If you want to know the results of the study, please leave with us your contact address 
so that we can send you a summary of the results after we have finished the study. We 
will not be able to give you your results alone or that of anyone else in this study, 
apart from the overall study results.  
Who can you call if you have questions? 
You can call me Dr. Donae George on my mobile 9442555421 or you can call 
Psychiatry Unit II office: 0416-2284520 during working hours and ask for me by 
name. You can also call the Psychiatry Unit II Office and ask to speak to Dr. Saumil 
Dholakia or Dr Prathap Tharyan. 
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INFORMED CONSENT FORM 1b 
Assessment of attitudes towards participation, willingness to participate, and 
competence to participate in Randomized Controlled Trials 
Title of the study : 
Dr. Donae George, Dr. Saumil Dholakia, Dr. Prathap Tharyan; Christian Medical 
College, Vellore 
Name of the investigators and institution: 
Study Number: 
Participant’s name:  
Date of Birth / Age (in years): 
Status: Inpatient/ relative of in-patient 
 
I________________________, son/daughter of ________________________declare 
that I have read the information sheet in _____________ provided to me/ had this 
information read out to me regarding this study and have clarified any doubts that I 
had.  
I understand that my participation in this study is entirely voluntary and that I am free 
to withdraw my decision to continue to participate at any time without affecting my 
medical care  / my relative’s medical care.  
I understand that during this study I will be required to take part in an interview 
conducted by Dr. Donae that will ask me my opinions about clinical research and 
discuss taking part in an imaginary study of a new medicine. I understand that this 
interview may last from half an hour to an hour or more.  
I understand that I will be also required to take part in another interview lasting for 
about half an hour conducted by Dr. Saumil that will ask me additional questions 
about my understanding about the details of the imaginary study.  
I understand that I am expected to cooperate with the interviews and answer the 
questions asked of me to the best of my ability. 
I understand that the interviews will be audio taped but my identity will not be 
revealed the opinions I express in the interview will not be used for purposes other 




I understand that all my opinions and information about me will be kept confidential 
and that my identity will not be revealed in any information released to third parties or 
if published in medical journals. 
I understand that participating in this study will not affect my clinical care nor will it 
benefit me directly.  I also understand that I will not be given any compensation for 
my participation.  
I also understand that the study staff and, if needed, the institutional ethics committee 
members, will not need my permission to look at my health records /my relative’s 
health records even if I withdraw from the trial.  
I consent to participate in this study and in the interviews conducted by Dr. Donae. 
I consent to participate in the interviews to be conducted by Dr. Saumil.  





Name of witness 
Relation to participant: 
Date: 
 
Key relatives consent: 
I, ____________________________, relative of ____________________________, 
have read the information provided and clarified my doubts. I consent to my relative 
participating in the trial as described in the information sheet. 
 










Data Extraction Sheet 
Patient Identification Details 
Date of assessment:  date of admission:        number of days since 
admission: 
Type of admission: voluntary/involuntary 
Serial No:  Psych Unit: Room category:  Hospital No: 
Patient Name:   age:    sex:    education: 
Literacy status: identify/understand/interpret/create/communicate/compute written 
and printed material: (tick as applicable) 
Occupation:   language: concession for treatment if any: 
Name of key relative: 
Relationship to the patient: 
Past history of psychiatric illness in key relative and details if any: 
Current evidence of psychiatric illness on clinical interview  in key relative(yes/no): 
Current medication in key relative (yes/no), if yes details: 
 
Disease profile: 
Diagnosis (ICD 10 code):    duration of illness (months): 
Duration of current exacerbation (months): 
Presence of active psychotic symptoms (delusions/hallucinations) in past 24 hrs: 
present/probable/unclear/absent: 
Insight (grade 1-6): 
Current medication: 






Present CGI score: 
 1. Severity of illness 
Considering your total clinical experience with this particular population, how 
mentally ill is the patient at this time? 
0 = Not assessed  
1 = Normal—not at all ill, symptoms of disorder not present past seven days 
2 = Borderline mentally ill—subtle or suspected pathology 
3 = Mildly ill—clearly established symptoms with minimal, if any, distress or 
difficulty in social and occupational function 
4 = Moderately ill—overt symptoms causing noticeable, but modest, functional 
impairment or distress; symptom level may warrant medication 
5 = Markedly ill—intrusive symptoms that distinctly impair social/occupational 
function or cause intrusive levels of distress 
6 = Severely ill—disruptive pathology, behavior and function are frequently 
influenced by symptoms, may require assistance from others 
7 = Among the most extremely ill patients—pathology drastically interferes in 




Attitudes to Research Questionnaire 
Information about this questionnaire: 
In the information provided to you earlier, I told you about the kind of research that is 
done to be sure a new medicine actually can result in benefit for people with specific 
medical or psychiatric conditions. I told you that in such studies (called RCTs or 
clinical trials), the patient and the doctor do not decide who is given the new medicine 
and who is not given a dummy medicine that looks identical to the new medicine, but 
that this is decided by a method similar to a lottery system. This is different from what 
you normally expect when you come to a hospital for treatment.  
People have varied views, opinion and beliefs regarding research and taking part in 
RCTs. These influence their choices of accepting/rejecting participation in them. We 
would like to know your views and request you to choose the single response to each 
question that most closely reflects what you feel about each question. There are no 
right or wrong answers as your views are important.  For each choice you make we 
will request you to give us reasons as to why you made that choice. We will be 
recording your answers so that we can accurately understand your opinions.  
Kindly circle the most appropriate response: 
1)  It is necessary to test new drugs scientifically before using them in clinical 
practice? 
Strongly agree----agree---------don’t know------disagree------strongly disagree. 
2) Patients take part in research trials because they expect to get personal health 
care and health benefits. 
Strongly agree----agree------don’t know--------disagree-------strongly disagree. 
3)  Doctors do research trials with a motive to “experiment” a new treatment 
option on the patient. 
Strongly agree---agree------don’t know---- disagree------- strongly disagree. 
4) Patients taking part in research trials do it mainly because they expect to get 
monetary benefits. 
Strongly agree-----agree----don’t know-----disagree------strongly disagree. 
5) Doctors do research trials as a way to promote their own careers. 
Strongly agree------agree----don’t know-----disagree------strongly disagree. 
6) Patients who participate in research do it because they believe that their 
participation will help in reducing human suffering as a whole. 




7) Doctors do research trial with the sole aim to help their patients. 
 Strongly agree------agree-----don’t know-------disagree-----strongly disagree. 
8) Patients find it very difficult to trust the motives of the doctors and the 
organization doing a clinical trial. 
 Strongly agree-----agree------don’t know-------disagree-------strongly disagree. 
9) Research trials of this nature are time consuming and interfere with the 
doctor’s work of looking after patients. 
 Strongly agree----agree------don’t know--------disagree------strongly disagree. 
10) Research trials of this nature do not fully address patients concerns about 
whether the drug is effective or safe  
 Strongly agree------agree------don’t know-------disagree------strongly disagree. 
11) For patients, faith in the doctor and the institution are the most important 
motivating factors behind deciding to take part in a clinical trial. 
 Strongly agree-----agree------don’t know-----disagree------strongly  disagree. 
12) The information provided in consent forms are very difficult for patients to 
understand. 
 Strongly agree-----agree-------don’t know-------disagree------strongly disagree. 
13) The decision to participate or not to participate in in a clinical trial is a family 
decision and cannot be taken by the patient alone. 
Strongly agree------agree-------don’t know-------disagree-----strongly disagree. 
14) Taking part in clinical trials usually results in others finding out confidential 
information about patients 
Strongly agree-----agree------don’t know------disagree--------strongly disagree. 
15) The methods of RCTs where patients and doctors do not have a choice in 
which treatment the patient is given is justified in order to be sure the new 
drug actually works. 
Strongly agree------agree------don’t know-------disagree---------strongly 
disagree. 
16) In RCTs, giving half the patients a dummy tablet that looks identical to a new 
medicine is not justified even if it is good way to do research 
Strongly agree------agree------don’t know-------disagree---------strongly 
disagree. 
17) If patients sign a consent form to take part in a RCT where they or the doctor 
have no choice in the treatment given and do not know if they are on treatment 
or a dummy tablet, then it is justified to use such methods. 





18) Involving patients in understanding more about research and helping to design 
how research should be done is not necessary. 
Strongly agree------agree------don’t know-------disagree---------strongly 
disagree. 
19) Since I enjoy the benefits of medicines because other people have taken part in 
research to prove the medicine works, I believe it is the duty of everyone to 
also take part in such research, if requested.  
Strongly agree------agree------don’t know-------disagree---------strongly 
disagree. 
20) If I were invited to take part in a  clinical trial of a new medicine compared 
against a dummy tablet, I will most probably agree to take part in this study 







Christian Medical College, Vellore 
Department of Psychiatry 
A randomized controlled trial comparing drug GVV278 with placebo in to reduce 
stress-related symptoms in people with psychiatric disorders  
Information sheet 
 
Invitation to participate in a randomized controlled trial (RCT) 
You are being requested to participate in a study to see if a new medicine called 
GVV278 can help reduce some of the symptoms of the psychiatric condition that you 
are admitted here for.  This study aims to recruit a minimum of 30 patients from this 
hospital and is also being conducted in other institutions in India and other countries 
to achieve a target sample size of 800 participants.  
[This study has been approved by the Institutional Review Board (Research and 
Ethics Committees) of the Christian Medical College, Vellore, as a hypothetical study 
(imaginary study) done as part of another study evaluating the attitudes of patients 
and participants on participating in clinical trials] 
What is the new medicine supposed to do? 
GVV278 has been shown in laboratory research to reverse the effects of stress in 
laboratory animals. It has been tried in research involving 20 people with no 
psychological problems who took GVV278 for over one year and experienced no 
troubling side effects at doses of 10 mg, 20 mg, and 30 mg taken orally in the 
morning after breakfast. Analysis of the effects of the different doses on 
psychological test performance of these people indicates that the 20 mg per day 
dose is the dose that is most likely to help reduce symptoms of stress.  
In one clinical trial involving 25 people from Brazil with different psychiatric 
conditions but who were also experiencing symptoms related to stress such as 
tiredness, headaches, sleep disturbance, and irritability, GVV278 was shown to be 
useful in reducing symptoms and reducing scores on psychiatric tests for symptoms 
of the underlying disorder. However, because this study involved only a small 
number of people and because GVV278 was not compared with a dummy tablet, 
doctors are not certain if the improvement seen in those given GVV278 in addition 
to their usual treatment was due to GVV278 or due to their usual treatment or due 
to chance.  
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There are also other drugs that can help in your problem and you may already be 
taking medication for your problem that is prescribed by your doctor. 
How does GVV278 act to help reduce stress related symptoms? 
It is not entirely clear how this drug acts as there are many chemical changes that 
take place in the brain that seem to work together to result in the effects that GVV 
278 has.  
Does GVV278 have any side effects? 
Some people on GVV278 have experienced some side effects such as headache, 
feeling anxious, feeling like vomiting, loose motion and stomach discomfort, but 
these were usually mild and temporary. GVV278 does not cause addiction or any 
problems when it is stopped suddenly. It may cause mild increases in blood pressure 
but these are usually not serious. It is not known to cause any problems to the heart.  
How is this research study designed to prove the effects of GVV278? 
This study will use a research design called a randomized controlled trial (or RCT) 
where every patient who is eligible and who consent to participate will be given an 
identical looking tablet to take after breakfast daily for 8 weeks. Half the participants 
in the trial will actually get GVV278 for the 8 weeks and the other half will get an 
identical looking tablet that does not contain GVV278 but contains only a small 
amount of sucrose (like sugar) that is unlikely to have any effect in the person taking 
it. The choice of who gets GVV278 or the dummy tablet has been decided by a 
computer that provided a code to the pharmacist of the company sponsoring this 
study in Switzerland. They have prepared serially-numbered containers containing 
one week’s supply of GVV or the dummy tablet, according to the randomization 
code. The doctors in this hospital conducting the study do not have access to this 
code and do not know what is in any of the tablets. This information is only known to 
the company sponsoring the trial. The doctors in this hospital are only provided with 
the serially numbered, coded medicine containers that have identical looking 
medicines for 8 weeks of treatment for the patients who will be recruited to the trial 
from this hospital. 
Since the selection of who gets which tablet will be decided by the code, we expect 
that this will result into equal selection of people in both groups especially with 
relation to  severity of symptoms.If this is not done, this may result in more sick 
people being selected to take GVV278 or the dummy tablet and we will not be sure if 
any difference in the results were due to any of the tablets or due to that fact that 
there were more sick people who got one of the tablets. We expect that by this 
method all people irrespective of the severity of symptoms will get an equal chance 
to get GVV278 or the dummy tablet 
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In addition, since both tablets are identical, the doctors who will decide if GVV278 or 
the dummy tablet causes more improvement, and patients who are taking part in 
the study will not be influenced by what they expect either tablet to do with regard 
to improvement in symptoms or in causing side effects, since nobody in this hospital 
knows who is taking GVV278 or the dummy tablet. Every week for the first month 
and at the end of 8 weeks, all participants in the study will be assessed for 
improvement in symptoms or the presence of side effects. Once these assessments 
are over the code will be opened and then statistical tests will be done to see if the 
differences in the results shows that GVV was better than the dummy tablet in 
improving symptoms and if there were more side effects with GVV or with the 
dummy tablet.  
This method is the best method to be sure of the effects of GVV on stress-related 
symptoms in people with psychiatric disorders.  
What will be expected of you if you agree to take part in this study? 
Once you agree to take part in this study, and have signed the informed consent 
form, your regular treatment will be changed during the period of this study and you 
will be given only a mild sedative for week, if you have sleep disturbance.  This is to 
be sure that all your previous medicines are no longer in your body. At the end of 
one week, I will assess you for your symptoms in a clinical interview and if you do not 
have enough symptoms your participation in the study will end and you will be 
requested to discuss with your treating team about whether you should continue on 
your usual medicines.  
If you still have troubling symptoms after a week, you will be asked to take one 
tablet every morning after breakfast for 8 weeks. This tablet will have either GVV or 
the dummy tablet but neither you nor I will know what is in the tablet you will be 
given. I will see you every day for the first four weeks during which you are expected 
to stay in the hospital as an in-patient. I will ask you for any side-effects due to the 
medicine you are taking.  
During this time you may experience worsening of your condition, including 
increased symptoms such as agitation, restlessness or decreased sleep. I will 
carefully monitor your condition and report it to your treating doctors as well. If your 
symptoms worsen and make you uncomfortable, you can withdraw from the study. 
You can do this at any time during the study, and you will be put back on your 
previous medicine. I will also ask you questions daily about your sleep, activities, and 
how you feel, in addition to asking you about any side effects. Your weight and blood 
pressure will also be recorded daily for as long as you are in hospital. No additional 
procedures or blood tests will be conducted routinely for this study.  
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If at any time you experience any problems, you will be expected to report this to 
me, or the nurses or to your doctor. If I or the other doctors in this study or your 
treating doctor feel that you are not showing satisfactory improvement or are 
getting worse on the tablet you are taking, we shall withdraw you from the study 
and you will be put back on your previous medicine.  
At the end of four weeks, you will be discharged if you are at least 50% better than 
when you started the new tablet. You will be contacted by telephone once a week by 
me or one of the doctors in this study who will ask you about any side effects that 
you are experiencing and rate your improvement by asking you questions about your 
sleep, appetite, mood, energy, and daily routine. 
At the end of 8 weeks, you will be expected to return for a final visit for the study 
where you will have all the assessments that were done on you at the start repeated 
and your weight and blood pressure monitored.  
If you are not at least 50% better by the end of four weeks, you will be expected to 
stay on as an inpatient and assessed every week. If you achieve 50% improvement at 
any of the weekly assessment, you will be discharged and followed up as described 
above.  
Can you withdraw from this study after it starts? 
Your participation in this study is entirely voluntary and you are also free to decide to 
withdraw permission to participate in this study, for any reason. If you do so, this will 
not affect your usual treatment at this hospital in any way. In addition, if you 
experience any serious side effects or your condition worsens, the study tablets will 
be stopped and you may be given additional treatment.  
What will happen if you develop any study related injury? 
We do not expect any serious injury to happen to you but if you do develop any side 
effects or problems due to the study, these will be treated at no cost to you. We are 
unable to provide any monetary compensation, however.  
Will you have to pay for the study tablets?  
Both GVV278 and the dummy tablets will be given free for a total period of 8 weeks. 
Your hospital charges for these eight weeks will also be made free, but you will have 
to pay for your food, if this is the usual arrangement you have with your treating 
doctor. In addition, you will also be reimbursed 250 Rs for any outpatient visit you 
make for the purposes of this study from the time you were discharged till the end of 
the study. If the cost you incur is more, this additional amount will also be 
reimbursed if you provide us the receipts or tickets. We will also reimburse 250 Rs 
(or any additional amount supported by tickets or receipts) for one family member 
to accompany you on these visits.  
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What happens after the study is over? 
You may or may not benefit from the study medicine that you are given. Once the 
study is over, if the tablet you were given is GVV278 and if it has helped you and you 
wish to continue, then your doctor may prescribe it for you. Otherwise, your treating 
doctor will help you decide on the best treatment for you to continue after the study 
is over. If you were given the dummy tablet and GVV278 has helped the people in 
this study who took it, then your doctor will give you the choice of taking GVV278. 
However, this will not be part of the study and you may have to pay for it. It may also 
take up to a year after the study for the government to approve GVV278 for sale in 
India as the results of treating people from all over India who take part in this trial 
will have to be analyzed. We may not be able to assure you a ready supply of 
GVV278 from the company till then, although the company has promised to give us 
stocks of the medicine.  
Will your personal details be kept confidential? 
The results of this study will be published in a medical journal but you will not be 
identified by name in any publication or presentation of results. However, your 
medical notes may be reviewed by people associated with the study, without your 
additional permission, should you decide to participate in this study.  
Who can you call if you have questions? 
You can call me Dr. Donae George on my mobile 9442555421 at any time, or you can 
call Psychiatry Unit II office: 0416-2284520 during working hours and ask for me by 
name. You can also call the Psychiatry Unit II Office and ask to speak to Dr. Saumil 




INFORMED CONSENT FORM 4a 
Title of the study: 
A randomized controlled trial comparing drug GVV278 with placebo in to reduce 
stress-related symptoms in people with psychiatric disorders 
 
Name of the investigators and institution: 




Participant’s name:  
Date of Birth / Age (in years): 
 
I______________________________, son/daughter of 
_______________________________ declare that I have read the information sheet 
in _____________ provided to me/ had this information read out to me regarding 
this study and have clarified any doubts that I had.  
In understand that I am being invited to participate in a research study that involves 
changing my current medicines, and being on no medicines for a week, except a mild 
sedative if needed.  I understand that I will be invited to take the study medicines 
only if I continue to have troubling symptoms after a week of stopping my current 
medicines. 
I understand that my participation in this study is entirely voluntary and that I am 
free to withdraw my decision to continue to participate at any time without affecting 
my medical care or my legal rights.  
I understand that during this study I will be required to take remain as an inpatient 
for 4 weeks at least and take one tablet every day for a total of 8 weeks.  
I understand that neither I nor any of the doctors in this hospital will have any choice 
in whether I am given GVV278 or a dummy tablet that looks identical to GVV278. 
This selection will occur by chance, as in a lottery, and I will have an equal chance of 
getting GVV278 or the dummy tablet. 
I understand that I will also have to cooperate with assessments for this study as 
explained to me in the information sheet.  
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I understand that I may or may not benefit by participation in this trial and that if I 
develop any study related injury, I will not receive any compensation, though I will 
be not be charged for the treatment of study related injury.  
I understand that the study medicines will be provided free of charge for 8 weeks 
and that if I chose to continue any of the study medicines after 8 weeks, I shall have 
to bear the costs. I also understand that a regular supply of the study medicine 
cannot be assured.  
I understand that all information about me will be kept confidential and that my 
identity will not be revealed in any information released to third parties or if 
published in medical journals. 
I also understand that the study staff and, if needed, the institutional ethics 
committee members, will not need my permission to look at my health records /my 
relative’s health records even if I withdraw from the trial.  





Name of witness 
Relation to participant: 
Date: 
 
Key relatives consent: 
I, ____________________________, relative of ____________________________, 
have read the information provided and clarified my doubts. I consent to my relative 
participating in the trial as described in the information sheet. 
 










Comprehension of information for the Hypothetical RCT on GVV278 versus placebo 
I shall ask you some questions to assess whether you have understood essential 
details about the RCT you were invited to participate in. If you are unsure of the 
answer to any of the questions, I shall clarify this information for you. 
I shall read out the questions loud and I will record your answers. This interview is 
also being recorded by voice recorder to make sure your replies are correctly 
understood.  
1. The new drug GVV278 has been found in previous research to be better than 
currently used medicines in treating symptoms of psychiatric conditions. 
True / False / Unsure / Other 
2. If you agree to take part in this study, your treating  doctor or I will decide 
whether you will get GV278 or the dummy tablet 
True / False / Unsure / Other 
3. If you agree to take part in this study, you will be given the study medicine as 
well as you usual medicines that you are now taking. 
True / False / Unsure / Other 
4. If you agree to take part in the study, you will be able to find out what medicine 
you have been given by asking one of the doctors or nurses in this hospital or the 
pharmacist at this hospital. 
True / False / Unsure / Other 
5. If you agree to take part in this study, you will be expected to take the study 
medicine for period of 4 weeks. 
True / False / Unsure / Other 
6. If you agree to take part in this study, you are likely to feel better whatever the 
medicine you are given. 
True / False / Unsure / Other 
7. If you agree to take part in this study, you are not likely to feel worse in any way, 
if you are actually given the new medicine GVV278. 
True / False / Unsure / Other 
8. If you agree to take part in this study, you will be given free food and 200 Rs per 
day 




9. If you agree to take part in this study, you will have blood tests done every week 
while you are in hospital 
True / False / Unsure / Other 
10. If you agree to take part in this study, and if you are given the dummy tablet, you 
are likely to feel worse than if you were given the new medicine GVV278.  
True / False / Unsure / Other 
Thank you for your time and for answering my questions. I will now discuss your 






















Clarifying questions and probes to assess barriers and facilitators to 
participation in a hypothetical RCT 
1. Willingness to participate in the RCT of GVV278 versus placebo 
Now that you have understood the information provided about the RCT 
comparing the new medicine GVV278, how likely is it that you will be willing to 




2. Open ended questions to clarify the choice  
 
What are the reasons for you to make the choice that you did? 
 
Probes: Were there any elements in the information provided about the 
study that influenced your choice? 
 
 Specific probes: Did the fact that your usual medicines would be withdrawn 
 give you concerns? 
 Did the fact that you would not have any choice in the drug you received 
 cause concern? 
Did the fact that your doctor would not have a choice in what medicine you 
got cause concern? 
Did the fact that a dummy tablet was used cause concern? 
Were there any other aspects of this trial that caused concern? 
 
If this had been a real trial, would you have changed your choice? 
Do you think trials like this should be done? 
Do you think that if your treating doctor recommended that you should take 
part in the trial, you would be more likely to agree to participate? 















 Extension 1 to the hypothetical RCT: information sheet and consent form 
Christian Medical College, Vellore 
Department of Psychiatry 
A randomized controlled trial comparing drug GVV278 with placebo in to reduce 
stress-related symptoms in people with psychiatric disorders-study extension 1 
 
The detailed information regarding the new medicine GVV278 was discussed with 
you during the first part of the study. Do you want me to repeat any of the 
information? In case the details are not clear to you, I would like to repeat it as 
follows. If it is clear to you, than we may move on to understanding what will be 
expected out of you if you decide to take part in this study extension. 
How is this research study designed to prove the effects of GVV278? 
This study will use a research design called a randomized controlled trial (or RCT) 
where every patient who fulfills the criteria for inclusion in the study and who 
consent to participate will be given an identical looking tablet to take after breakfast 
daily for 8 weeks. Half the participants in the trial will actually get GVV278 for the 8 
weeks and the other half will get an identical looking tablet that does not contain 
GVV278 but contains only a small amount of sucrose (like sugar) that is unlikely to 
have any effect in the person taking it. The choice of who gets GVV278 or the 
dummy tablet has been decided by a computer that provided a code to the 
pharmacist of the company sponsoring this study in Switzerland who prepared 
serially-numbered containers containing one week’s supply of GVV or the dummy 
tablet, according to the randomization code. The doctors in this hospital conducting 
the study do not have access to this code and do not know what is in any of the 
tablets. This information is only known to the company sponsoring the trial. The 
doctors in this hospital are only provided with the serially numbered, coded 
medicine containers that have identical looking medicines for 8 weeks of treatment 
for the patients who will be recruited to the trial from this hospital. 
Since the selection of who gets which tablet will be decided by the code, this will 
prevent anyone selecting sicker (people with more severe symptoms) to take either 
GVV27 or the dummy tablet for any reason. If this is not done, this may result in 
more sick people being selected to take GVV278 or the dummy tablet and we will 
not be sure if any difference in the results were due to any of the tablets or due to 
that fact that there were more sick people who got one of the tablets. We expect 
that by this method there will be equal numbers of people who have more severe 
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symptoms and those who have less severe symptoms who will get GVV278 and the 
dummy tablet 
In addition, since both tablets are identical, the doctors who will decide if GVV278 or 
the dummy tablet causes more improvement, and patients in the study who are 
taking the tablets and who will report to the doctors about any benefits or side 
effects of the treatment, will not be influenced by what they expect either tablet to 
do with regard to improvement in symptoms or in causing side effects, since nobody 
in this hospital knows who is taking GVV278 or the dummy tablet. Every week for the 
first month and at the end of 8 weeks, all participants in the study will be assessed 
for improvement in symptoms or the presence of side effects. Once these 
assessments are over the code will be opened and then statistical tests will be done 
to see if the differences in the results shows that GVV was better than the dummy 
tablet in improving symptoms and if there were more side effects with GVV or with 
the dummy tablet.  
This method is the best method to be sure of the effects of GVV on stress-related 
symptoms in people with psychiatric disorders.  
What will be expected of you if you agree to take part in this study? 
Once you agree to take part in this study, and have signed the informed consent 
form, your regular treatment will continue as prescribed by your treating doctor 
during the period of this study and you will not be expected to make any changes to 
these medicines for the 8 weeks of the trial.   
At the start of the study, you will be asked to take one tablet every morning after 
breakfast for 8 weeks. This tablet will have either GVV or the dummy tablet but 
neither you nor I will know what is in the tablet you will be given. I will see you every 
day for the first four weeks during which you are expected to stay in the hospital as 
an in-patient. I will ask you for any side-effects due to the medicine you are taking.  
During this time you may experience worsening of your condition although we are 
uncertain whether this will occur of what symptoms might be caused. I will carefully 
monitor your condition and report it to your treating doctors as well. If your 
symptoms worsen and make you uncomfortable, you can withdraw from the study. 
You can do this at any time during the study, and you will be put back on your 
previous medicine. I will also ask you questions daily about your sleep, activities, and 
how you feel, in addition to asking you about any side effects. Your weight and blood 
pressure will also be recorded daily for as long as you are in hospital.  
Since we wish to make sure that the combination of GV278 and your usual medicines 
will not cause any problems, if you agree to take part in this extension study, we will 
perform blood tests to check your liver functions, kidney functions etc. at the start of 
the study and weekly for the first four weeks and at the end of 8 weeks. We will 
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withdraw about 10 ml of blood each time. Any remaining blood after the tests will be 
discarded. In addition, we will perform an EEG to assess your brain electrical activity 
and an ECG to assess your heart’s electrical activity at the beginning and the end of 
the study. The EEG and the ECG will be done in the laboratories of the main CMC 
Hospital by special appointment and will be painless procedures. We will provide 
more information about these procedures once you agree to participate.  
If at any time you experience any problems, you will be expected to report this to 
me, or the nurses or to your doctor. If I or the other doctors in this study or your 
treating doctor feel that you are not showing satisfactory improvement or are 
getting worse on the tablet you are taking, we shall withdraw you from the study 
and you will be put back on your previous medicine.  
At the end of four weeks, you will be discharged if you are at least 50% better than 
when you started the new tablet. You will be contacted by telephone once a week by 
me or one of the doctors in this study who will ask you about any side effects that 
you are experiencing and rate your improvement by asking you questions about your 
sleep, appetite, mood, energy, and daily routine. 
At the end of 8 weeks, you will be expected to return for a final visit for the study 
where you will have all the assessments that were done on you at the start repeated 
and your weight and blood pressure monitored.  
If you are not at least 50% better by the end of four weeks, you will be expected to 
stay on as an inpatient and assessed every week. If you achieve 50% improvement at 
any of the weekly assessment, you will be discharged and followed up as described 
above.  
Can you withdraw from this study after it starts? 
Your participation in this study is entirely voluntary and you are also free to decide to 
withdraw permission to participate in this study, for any reason. If you do so, this will 
not affect your usual treatment at this hospital in any way. In addition, if you 
experience any serious side effects or your condition worsens, the study tablets will 
be stopped and you may be given additional treatment.  
What will happen if you develop any study related injury? 
We do not expect any serious injury to happen to you but if you do develop any side 
effects or problems due to the study, these will be treated at no cost to you. We are 
unable to provide any monetary compensation, however.  
Will you have to pay for the study tablets?  
Both GVV278 and the dummy tablets will be given free for a total period of 8 weeks. 
Your hospital charges for these eight weeks will also be made free, but you will have 
to pay for your food, if this is the usual arrangement you have with your treating 
127 
 
doctor. In addition, whatever medicine you are being prescribed at the start of the 
study will also be paid for and you will not have to pay for them. All the 
investigations associated with the study will also be done free of cost. 
You will also be reimbursed 250 Rs for any outpatient visit you make for the 
purposes of this study from the time you were discharged till the end of the study. If 
the cost you incur is more, this additional amount will also be reimbursed if you 
provide us the receipts or tickets. We will also reimburse 250 Rs (or any additional 
amount supported by tickets or receipts) for one family member to accompany you 
on these visits.  
What happens after the study is over? 
You may or may not benefit from the study medicine that you are given. Once the 
study is over, if the tablet you were given is GVV278 and if it has helped you and you 
wish to continue, then your doctor may prescribe it for you. Otherwise, your treating 
doctor will help you decide on the best treatment for you to continue after the study 
is over. In all cases once the study is over, the decision to continue your medicine 
will be made by your treating doctor in collaboration with you. If you were given the 
dummy tablet and GVV278 has helped the people in this study who took it, then 
your doctor will give you the choice of taking GVV278. However, this will not be part 
of the study and you may have to pay for it. It may also take up to a year after the 
study for the government to approve GVV278 for sale in India as the results of 
treating people from all over India who take part in this trial will have to be analyzed. 
We may not be able to assure you a ready supply of GVV278 from the company till 
then, although the company has promised to give us stocks of the medicine.  
Will your personal details be kept confidential? 
The results of this study will be published in a medical journal but you will not be 
identified by name in any publication or presentation of results. However, your 
medical notes may be reviewed by people associated with the study, without your 
additional permission, should you decide to participate in this study.  
Who can you call if you have questions? 
You can call me Dr. Donae George on my mobile 9442555421 at any time, or you can 
call Psychiatry Unit II office: 0416-2284520 during working hours and ask for me by 
name. You can also call the Psychiatry Unit II Office and ask to speak to Dr. Saumil 







INFORMED CONSENT FORM 4d 
Title of the study: 
A randomized controlled trial comparing drug GVV278 with placebo in to reduce 
stress-related symptoms in people with psychiatric disorders-Study extension 1 
 
Name of the investigators and institution: 




Participant’s name:  
Date of Birth / Age (in years): 
 
I______________________________, son/daughter of 
_______________________________ declare that I have read the information sheet 
in _____________ provided to me/ had this information read out to me regarding 
this study and have clarified any doubts that I had.  
In understand that I am being invited to participate in a research study that involves 
continuing on my current medicines and adding a new medicine GVV278 or a 
dummy tablet for a period of 8 weeks.  
I understand that my participation in this study is entirely voluntary and that I am 
free to withdraw my decision to continue to participate at any time without affecting 
my medical care or my legal rights.  
I understand that during this study I will be required to take remain as an inpatient 
for 4 weeks at least and take one tablet every day for a total of 8 weeks.  
I understand that neither I nor any of the doctors in this hospital will have any choice 
in whether I am given GVV278 or a dummy tablet that looks identical to GVV278. 
This selection will occur by chance, as in a lottery, and I will have an equal chance of 
getting GVV278 or the dummy tablet. 
I understand that I will also have to cooperate with assessments for this study as 
explained to me in the information sheet. These assessments include blood tests and 
EEG and ECG tests as described in the information sheet. 
I understand that I may or may not benefit by participation in this trial and that if I 
develop any study related injury, I will not receive any compensation, though I will 
be not be charged for the treatment of study related injury.  
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I understand that the study medicines  and my regular medicines will be provided 
free of charge for 8 weeks and that if I chose to continue any of the medicines after 8 
weeks, I shall have to bear the costs, or discuss this with my treating doctor. I also 
understand that a regular supply of the study medicine cannot be assured.  
I understand that all information about me will be kept confidential and that my 
identity will not be revealed in any information released to third parties or if 
published in medical journals. 
I also understand that the study staff and, if needed, the institutional ethics 
committee members, will not need my permission to look at my health records even 
if I withdraw from the trial.  
 






Name of witness 
Relation to participant: 
Date: 
 
Key relatives consent: 
I, ____________________________, relative of ____________________________, 
have read the information provided and clarified my doubts. I consent to my relative 
participating in the trial as described in the information sheet. 
 










Comprehension of information for the Hypothetical RCT on GVV278 versus 
placebo-extension 1 
 
I shall ask you some questions to assess whether you have understood essential 
details about the RCT you were invited to participate in. If you are unsure of the 
answer to any of the questions, I shall clarify this information for you.  
I shall read out the questions loud and I will record your answers. This interview is 
also being recorded by voice recorder to make sure your replies are correctly 
understood.  
 
1. The new drug GVV278 has been found in previous research to safe when 
given along with your currently used medicines in treating symptoms of 
psychiatric conditions. 
 True / False / Unsure / Other 
2. If you agree to take part in this study, you will be given the study medicine as 
well as you usual medicines that you are now taking. 
 True / False / Unsure / Other 
3. If you agree to take part in this study, you are not likely to feel worse in any 
way, if you are actually given the new medicine GVV278. 
 True / False / Unsure / Other 
4. If you agree to take part in this study, you will not have to pay for your usual 
medicines for the period of the study. 
 True / False / Unsure / Other 
5. If you agree to take part in this study, you will have an EEG and an ECG done 
every week while you are in hospital 
 True / False / Unsure / Other 
 
Thank you for your time and for answering my questions. I will now discuss your 
answers with you. 
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Appendix 4 f 
Clarifying questions and probes to assess barriers and facilitators to 
participation in a hypothetical RCT- extension 1 
 
1. Willingness to participate in the RCT of GVV278 versus placebo- extension 1 
Now that you have understood the information provided about the RCT comparing 
the new medicine GVV278, in this extension study how likely is it that you will be 
willing to sign the informed consent document to participate in the study? 
Most unlikely to participate- probably unlikely—unsure---probably likely--- most 
likely to participate 
2. Open ended questions to clarify the choice  
What are the reasons for you to make the choice that you did? 
Probes:  Were there any elements in the information provided about the study 
that influenced your choice? 
Were there any elements in the information not provided about the 
study that influenced your choice? 
 
Specific probes:   
Did the fact that your usual medicines would be continued influence your decision?  
Did the fact that you would have to undergo blood tests cause concern? 
Did the fact that you would have to undergo an ECG cause concern? 
Did the fact that you would have to have an EEG cause concern? 
Were there any other aspects of this trial that caused concern? 
If this had been a real trial, would you have changed your choice? 
Would you prefer to participate in this extension trial or the previous trial? 
Do you think patients and relatives should be involved in helping to design research 







A randomized trial comparing drug GVV278 with placebo to reduce stress related 
symptoms in people with psychiatric disorders. 
MacCAT-CR  interview form: 
The purpose of our discussion is to know your understanding of imaginary 
randomized control trial with drug GVV278 (and its extension if applicable) that you 
have been invited to join. Please do not hesitate to ask any questions as the 
interview proceeds.  
Understanding section: 
(Question 1 is a modified question as PI has already gone through the details of 
project in the information sheet; hence only some details are repeated) 
1) Dr. Donae has discussed with about the imaginary research project with drug 
GVV278 to reduce stress. The project will last for 8 weeks for which you 
would be staying as inpatient. Your previous medications will be stopped. 
You would be assessed daily about your sleep, activities and your feelings. 
Your weight and blood pressure would be daily monitored. You would be 
asked daily about any side effects.  
Question:  
Do you have any questions about what i just said/what has been told to you by Dr. 
Donae? 
Can you tell your understanding of what i just said? 
Probe:   (if the subject fails to respond spontaneously)    
• What is the purpose of the research project i described to you? 
• How long will the research project last? 
• What sort of things will be done with people who agree to take part in the 
study? 
• What else would be done with people who agree to be in the study? 
2) it is important that you understand that the project in which you have been asked 
to take part is a research project and not a part of your treatment.  That means that 
the main purpose is to help doctors decide whether the drug GVV278 can help some 





Do you have any questions about what I just said? 
Can you tell your understanding of what I just said? 
Probe:  
• What is the main purpose of what the doctors are trying to do in this study? 
3) Because this is a research project and not ordinary treatment, the doctors will be 
doing things that they would not do in ordinary hospitals or clinics, like those where 
you may have been treated before. For example out of all the people who agree to 
take part in this study’ some people in this project will get GVV278 but others will 
get a dummy pill (called a placebo). The pill will not have any medicine in it. Whether 
they get GVV278 or the dummy pill will be decided by chance. Neither the doctors 
nor the subjects will know whether they are getting the new medication or the 
dummy pill. All these things are done to see whether GVV278 is better than no 
medication at all.  
Question:  
Do you have any questions about what I just said? 
Can you tell your understanding of what I just said? 
Probe:  
• Will all people in the project get the new medicine? 
• How will it be determined what kinds of pills each of the people in the project 
will receive? 
• Who will know which kind of pill is received by which people? 
 
4) There are several benefits that could result if people agree to be in this project. 
One of the most important benefit is that the doctors would come to know 
whether the GVV278 really does work with people who have stress related 
symptoms in people with psychiatric disorders. Secondly, for people in the project 
who actually get GVV278 will be able to find out whether or not it works for them. 
Question:  
Do you have any questions about what I just said? 





• What might doctors learn about the treatment of stress related symptoms in 
people with psychiatric disorder s if people decide to take part in this 
research project? 
• In what way might people benefit by volunteering to take part in this study? 
 
5) There are also several risks and discomforts to which people in this study might 
encounter. Firstly, GVV278 can cause mild problems like headache, nausea, 
stomach discomfort and loose motions.  It may also cause a mild increase in  
blood pressure. Secondly, all people in the study would be interviewed on a daily 
basis for at least 4 weeks and maximum 8 weeks which might cause some 
discomfort to participants.  
Question:  
Do you have any questions about what I just said? 
Can you tell your understanding of what I just said? 
Probe:  
• What unpleasant effects can the medication cause in some people? 
• What can cause some discomfort to most people who take part in the 
study? 
6) It is not compulsory to be a part of this project. People who agree to be in this 
research project can change their minds at any time. If they donot agree to be in 
this project or if they decide to stop, their usual treatment would be restarted. 
Question:  
Do you have any questions about what I just said? 
        Can you tell your understanding of what I just said? 
Probe: 
• What would happen if a person refuses to be in the research project, or 
decides to stop once it begins? 
Appreciation: 
7) a) Do you believe that you have been asked to be in this project mainly for your 
personal benefit? 
b) What makes you say so? 
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       8) a) do you believe that you could get the dummy pill? 
       b) What makes you say so? 
 9)  a) what do you believe would happen if you were to decide not to be in this 
 study? 
       b) What makes you say so? 
Expressed choice: 
10) As you know, you have been invited to participate in this research project to test 
a drug named GVV278 for treatment of stress in people with psychiatric disorders. 
What do you think you are more likely to do—would you want to participate or 
decline the invitation to participate? 
Reasoning 
11) You think you are more likely to___________ in the study. Tell me what is it that 
makes you think that this option is better than the other.  
12) I told you about some of the possible benefits and risks and discomforts of 
participating in the research project. The benefits are that those subjects who 
actually get GVV278 may find out whether it works for them. The risks and 
discomforts are that GVV278 can cause headache, nausea, stomach discomfort, a 
mild increase in blood pressure and all people in the study will have to answer a set 
of questions every day. Can you tell me in what way this would affect your everyday 
activities if you participate in this research project? 
Probe:  
• How might benefits or risks and discomfort affect your everyday life? 
13) A few minutes ago you told me that you are more likely to favour 
participating/not participating in the research project. Now that we have discussed 
everything, what do you want to do? 
Logical consistency of choice: interviewer records and explains the presence or 
absence of logical consistency in subject’s choice. If consistant, no probe required. If 
not, then the inconsistencies be discussed with the subject until the interviewer 






















MacCAT-CR Record form 
Subject:..........................    
 interviewer:............................... 
Record ID#:....................     
 Date:.......................................... 
Understanding (each item is rated 0-2) 




d)__________      subtotal: 
 
2) Primary purpose is research 
Subtotal: 
3) Effects on individualized care 
a)___________ 
b)___________ 
c)___________      subtotal: 
 




d)____________     subtotal: 
 
5) Ability to withdraw 
Subtotal: 
 
Total UNDERSTANDING SCORE (0-26): 
 
 
APPRECIATION: ( each item is rated 0-2) 
1) Object  not personal benefit:________ 
2) Possibility of reduced benefit:_______ 









Reasoning: (each item is rated 0-2) 
1) Consequential reasoning:________ 
2) Comparative reasoning:_________ 
3) Generating consequences:________ 
4) Logical consistency of choice:________ 
Total REASONING SCORE (0-8): 
 
 
EXPRESSING A CHOICE: (rate 0-2) 
_______________ 
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